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ABSTRACT
Lysophosphatidic acid (LPA) and transforming growth factor beta (TGFβ) are
platelet-derived intercellular mediators of cell proliferation and motility. LPA is a general
growth, survival and motility-stimulating factor in mammalian cells. TGFβ prevents
proliferation of normal epithelial cells. However, the growth-inhibitory effect of TGFβ is
lost or reduced in most malignant cells. Instead, TGFβ promotes migration and invasion
of advanced cancer cells. Since LPA and TGFβ are both present in the blood and tumor
microenvironments, we were interested in signal integration and functional outcomes in
malignant epithelial cells in an LPA and TGFβ co-stimulatory context. In a subset of
breast and ovarian cancer cell lines which remain sensitive to the cytostatic effect of
TGFβ, we found that LPA up-regulated expression of the cyclin-dependent kinase
inhibitor p21Waf1. But this up-regulation was not observed in TGFβ-resistant ones. We
examined the possibility that LPA-induced p21 might contribute to the cytostatic
response to TGFβ. Indeed, TGFβ alone induced p21 expression weakly in TGFβsensitive cells. Serum or serum-borne LPA cooperated with TGFβ to elicit the maximal
p21 induction. LPA stimulated p21 via LPA1 and LPA2 receptors and Erk-dependent
activation of the CCAAT/enhancer-binding protein beta (C/EBPβ) transcription factor
independent of p53. Loss or gain of p21 expression led to a shift between TGFβ sensitive
and resistant phenotypes in breast and ovarian cancer cells, indicating that LPA-induced

xiii

p21 is a key determinant of the growth inhibitory activity of TGFβ. The p21-stimulatory
action of LPA is absent from most breast and ovarian cancer cells, leading to their
resistance to TGFβ. Therefore we reveal a novel crosstalk between LPA and TGFβ that
underlies TGFβ sensitive and resistant phenotypes of breast and ovarian cancer cells.
In the next part of our study, we examined the role of interactions between LPA
and TGFβ in regulation of tumor cell motility. LPA and, to a much less extent, TGFβ
stimulate chemotactic migration and invasion of breast and ovarian cancer cells. However,
when combined together with LPA, TGFβ strongly attenuated LPA-driven migration and
invasion of breast and ovarian cancer cells. This inhibitory effect was most likely
mediated through TGFβ downregulation of expression of LPA1, the major receptor
subtype responsible for LPA-regulated cell migration. Knockdown of Smad3 or Smad4
with small hairpin RNA (shRNA) eliminated the inhibitory effects of TGFβ on the LPA1
expression and LPA-dependent cell migration. There are two potential TGFβ inhibitory
elements (TIE) (-40 bp and -401 bp) present in the human LPA1 gene promoter. Deletion
or point mutation of the distal TIE at around -401 bp abolished the inhibitory effect of
TGFβ on the LPA1 promoter activity as revealed by luciferase assays. A DNA pull-down
assay showed that the -401-TIE-E2F4/5 sequence was capable of binding Samd3, Smad4,
and E2F4/5 in TGFβ-treated cells. The binding of the Smad complex to the native TIEE2F4/5 sequences of the LPA1 gene promoter was further verified by chromatin
immunoprecipitation assay. Our results identify a novel role of TGFβ in the control of
LPA1 expression and LPA1-coupled biological activities, adding LPA1 to the list of
TGFβ-repressed target genes.
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CHAPTER 1

INTRODUCTION

1.0 Overview
Breast cancer and ovarian cancer are leading causes of cancer-related death in
women. An estimate of 288,130 new cases of breast cancer and 22,280 new cases of
ovarian cancer are expected in the United States during 2012. Most breast cancers are
derived from the epithelial cells that line the terminal ducts or lobules (Sainsbury et al
1994). Breast cancer stages are expressed as a number on a scale of 0 through IV (Stage 0
describing non-invasive cancers that remain within the original location and stage IV
describing invasive cancers that have spread beyond the breast and near lymph nodes to
other organs of the body, such as the lungs, distant lymph nodes, skin, bones, liver or
brain). Pleural effusions may occur at any point of the clinical course of breast tumor
progression and may be the sole manifestation of metastatic disease (Dieterich et al 1994).
Approximately 10-20% breast cancers are triple-negative, the breast tumor type tested
negative for estrogen receptors (ER-), progesterone receptor (PR-) and HER2 (HER2-).
Therefore, the triple-negative breast cancer does not respond to hormonal therapy or
target therapy against the HER2 receptor. The most common type of ovarian cancer is

1

ovarian epithelial carcinoma. Ovarian cancer is classified into four stages (Stages I-IV).
At the advanced stages III and IV, it is often characterized by extensive intra-peritoneal
distribution of tumors and formation of large volumes of ascites.
Malignant pleural effusions of breast cancer and ascites of ovarian cancer
represent tumor microenvironments enriched with a broad spectrum of intercellular
mediators including lysophosphatidic acid (LPA) (Mills et al 1990, Moolenaar et al 1992,
Xu et al 1995a) and transforming growth factor beta (TGFβ) (Hirte and Clark 1991).
Both LPA and TGFβ are elevated in ovarian cancer ascites compared to non-malignant
fluids (Ikubo et al 1995, Xu et al 1995b, Xu et al 1998). Previous studies of these
coexisting factors have been restricted to analysis of the biological activities of individual
ones without consideration of their simultaneous effects (Massague 2008, Mills and
Moolenaar 2003). The results from these prior studies may not reflect their physiological
roles in vivo. In the present study, we explored the potential crosstalk between LPA and
TGFβ signaling in breast and ovarian carcinoma cells. Our results establish that such
crosstalk indeed exists and operates to determine ultimate proliferative and migratory
responses of breast and ovarian cancer cells.

1.1 LPA

1.1.1 Metabolism of LPA
LPA

(1-acyl-2-hydroxy-sn-glycero-3-phosphate)

is

the

simplest

natural

phospholipid. LPA can be produced by multiple cell types, including activated platelet
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(Eichholtz et al 1993), endothelial cells (Siess et al 1999), fibroblasts (van der Bend et al
1992), adipocytes (Valet et al 1998), and cancer cells (Bektas et al 2005, Fang et al
2000a). LPA is present in body fluids including plasma, saliva, hair follicles and
malignant effusions (Aoki et al 2008, Sugiura et al 2002) and accounts for many
biological properties of serum. In addition to 1-acyl LPA, other LPA species such as
cyclic LPA, 1-alkyl and 1-alkenly-LPA are also found in serum and ovarian cancer
patient ascites (Kobayashi et al 1999, Xiao et al 2001).
Two main pathways are involved in endogenous generation of LPA from other
phospholipids (Aoki et al 2002, Aoki 2004). Activated platelet, which is responsible for a
major part of LPA production in vivo, generates LPA by sequential actions of
phospholipases present in plasma or expressed by blood cells. Two phospholipases,
secretory phospholipase A2 (sPLA2) and phospholipase A1 (PLA1) are involved in the
production

of

lysophospholipids

lysophosphatidylethanolamine

(LPE),

such
and

as

lysophosphatidylcholine

lysophosphatidylserine

(LPS).

(LPC),
These

lysophospholipids are converted to LPA by action of lysophospholipase D (lysoPLD)
(Aoki et al 2002). The lysoPLD responsible for LPA production has been identified as
autotaxin (ATX) (Umezu-Goto et al 2002), a previously enigmatic ecto-enzyme involved
in tumor invasion, neovascularization and metastasis (Nam et al 2000, Ptaszynska et al
2008, Yang et al 2002). With its intrinsic lysoPLD activity, ATX can hydrolyze LPC, a
major phospholipid secreted by hepatocytes and therefore abundant in the blood, into
LPA. The recently reported crystal structure of ATX suggests that the binding of ATX to
integrins localizes LPA production to platelets and mammalian cells (Fulkerson et al
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2011). Another potential pathway of LPA production independent of PLA and ATX is
direct phosphorylation of monoacylglycerol (MAG) by acylglycerol kinase (AGK)
(Bektas et al 2005). Overexpression of AGK is associated with increased production and
secretion of LPA (Bektas et al 2005).
The lipid phosphate phosphotases (LPPs) are a family of enzymes that remove the
phosphate group from LPA and convert LPA to MAG (Pilquil et al 2001, Tomsig et al
2009, Xu et al 2000). These LPPs are membrane-associated with extracellularly facing
catalytic site for dephosphorylating LPA on the cell membrane. Expression of LPPs
reduced endogenous LPA levels and attenuated LPA-mediated cellular functions (Tomsig
et al 2009). Other than dephosphorylation, LPA can also be converted to phosphatidic
acid (PA) by acylation through the action of LPA acyl transferases (LPAAT) (Eberhardt
et al 1997, Leung 2001).

1.1.2 LPA receptors and signal transduction
LPA is a mediator of diverse biological processes including neurogenesis,
angiogenesis, wound healing, immunity, and carcinogenesis (Panupinthu et al 2010).
These biological functions of LPA are mediated through binding of LPA to its seventransmembrane G-protein coupled receptors (GPCRs). To date, six GPCRs have been
identified as physiological LPA receptors. Based on their amino acid homology, the LPA
receptors are classified into two different groups: LPA1/Edg2, LPA2/Edg4 and
LPA3/Edg7 share more than 50% amino acid identity and belong to the endothelial
differentiation gene (Edg) family, whereas GPR23/P2Y9/LPA4 of the purinergic receptor
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family and the related GPR92/LPA5, and P2Y5/LPA6 and GPR87/LPA7 are non-Edg
LPA receptors or novel subgroup of LPA receptors (Choi et al 2010) (Figure 1.1).

Figure 1.1. A representative phylogenetic tree of human GPCRs. Adapted from
Keisuke Yanagida and Satoshi Ishii, “Non-Edg family LPA receptors: the cutting edge
of LPA research”, J Biochem, (2011) 150 (3): 223-232.

LPA1 is the first high-affinity receptor identified for LPA (Hecht et al 1996). It is
widely expressed in embryonic cells and adult tissues including brain, uterus, testis, lung,
small intestine, heart, stomach, kidney, spleen, thymus, placenta, and skeletal muscle (An
et al 1998, Contos et al 2000b). LPA1 is expressed in neoplastic cells as well. However,
gene expression profiling studies failed to show any consensus increase in LPA1
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expression between normal and malignant cells (Hendrix et al 2006, Radvanyi et al 2005,
Sanchez-Carbayo et al 2006, Skrzypczak et al 2010, Su et al 2007). Instead, some
expression profiling or array analyses suggest decreases in LPA1 mRNA expression in
various malignancies (Hendrix et al 2006, Sanchez-Carbayo et al 2006, Shida et al 2004b,
Skrzypczak et al 2010, Su et al 2007).
Only minor abnormalities such as craniofacial dysmorphism and defective
sucking behavior were found in LPA1-deficient mice (Contos et al 2000a). However,
further analysis of these LPA1 knockout mice subjected to pathophysiological conditions
has revealed that LPA1 is required for the initiation of neuropathic pain (Inoue et al 2004)
and promotion of pulmonary and renal fibrosis (Pradere et al 2007, Tager et al 2008).
More recent studies suggested the importance of LPA1 in neurogenesis (Matas-Rico et al
2008), hippocampus synaptic function (Musazzi et al 2011), and bone development
(Gennero et al 2011).
LPA2 was identified from GenBank searches of orphan GPCRs. It exhibits about
60% amino acid similarity to LPA1 (Contos and Chun 2000). The expression of LPA2 is
relatively restricted. High expression of LPA2 is detected in testis and leukocytes, and
moderate expression is found in prostate, spleen, thymus, and pancreas (An et al 1998).
Our group is the first to report overexpression of LPA2 in early and late stages of ovarian
cancer (Fang et al 2000a, Fang et al 2002). In breast cancer, LPA2 overexpression is
observed in more than half (57%) of the most common invasive ductal carcinoma
(Kitayama et al 2004). LPA2 is also commonly overexpressed in gastric cancer
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(Yamashita et al 2006), differentiated thyroid cancer (Schulte et al 2001) and other
human malignancies (Schulte et al 2001). Mice lacking LPA2 do not show any significant
abnormalities in physiology (Contos et al 2002). However, compared to wild type mice,
LPA2-deficient mice are more resistant to intestinal tumor formation induced by colitis or
by ApcMin mutation (Lin et al 2009, Lin et al 2010). These studies together are
consistent with an oncogenic role for LPA2.
LPA3 was isolated as an orphan GPCR gene using degenerate PCR-based cloning
and homology searches (Bandoh et al 1999, Im et al 2000). Expression of LPA3 is
observed in heart, testis, prostate, pancreas, lung, ovary, and brain (Bandoh et al 1999, Im
et al 2000). LPA3 is overexpressed in about 45% of ovarian cancers (Fang et al 2002) but
not as commonly overexpressed as LPA2 in many other types of cancer. Homozygous
deletion of LPA3 leads to identification of a specific function of this LPA receptor in
female reproduction. LPA3 deficient female mice show a delayed implantation and
defective embryo spacing, associated with reduced uterine expression of Cox-2 mRNA
(Ye et al 2005).
LPA4 is the first non-Edg LPA receptor identified through ligand screening
(Noguchi et al 2003). Its mRNA is expressed in various human tissues with the highest
abundance in the ovary (Noguchi et al 2003). Interestingly, LPA4 expression is
undetectable or generally low in most tumor cell lines. Our lab generated LPA4 knockout
mice. LPA4 null mice did not show apparent abnormalities compared to the wild type
littermates. However, LPA4 seems to negatively regulate cell motility in that LPA4-
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deficient mouse embryo fibroblasts (MEFs) are more sensitive to LPA-induced migration
(Lee et al 2008). Similarly, overexpression of LPA4 suppresses LPA1-mediated cell
migration in cancer cell lines (Lee et al 2008).
More recently, the orphan GPR92 was identified as another non-Edg LPA
receptor, LPA5. It shares about 35% amino acid homology with LPA4 (Lee et al 2006).
LPA5 is broadly expressed in murine tissues such as embryonic brain, small intestine,
skin, spleen, stomach, thymus, lung, heart, liver and embryonic stem cells (Kotarsky et al
2006, Lee et al 2006). Antagonists study of LPA5 suggests its role in activation of
platelets (Williams et al 2009).
P2Y5/LPA6 mRNA is expressed in spleen, thymus, leukocyte, prostate, ovary,
testis, small intestine, and colon (Pasternack et al 2008). LPA6 is found to be mutated in
hypotrichosis simplex and required for maintenance of human hair growth (Pasternack et
al 2008). The LPA6 knockout mice have not been reported but would be expected to
phenocopy the major function of the human receptor in regulating hair growth.
GPR87/LPA7 is expressed at low levels in most tissues with the exception of
prostate, placenta, head and neck. An interesting observation with GPR87 is its
overexpression specifically in squamous cell carcinomas of the lung, cervix, skin, urinary
bladder, testis, head and neck (Tabata et al 2007). Other orphan GPCRs such as P2Y10
(Murakami et al 2008) and GPR35 (Oka et al 2010) have been also proposed to be
additional LPA receptors. However, their identities as bona fide receptors for LPA are yet
to be validated through independent studies.

8

Like other GPCRs, LPA receptor subtypes appear to couple to multiple
heterotrimeric G proteins that in turn, activate diverse pathways including stimulation of
phospholipase C and D, small GTPases, mitogen-activated protein kinases (MAPK), and
phosphatidylinositol 3-kinase (PI3K) (Bandoh et al 1999, Contos et al 2002, Fukushima
et al 2002, Im et al 2000, Lee et al 2006, Mills and Moolenaar 2003). Activation of these
diverse G protein signaling cascades downstream of LPA receptors culminates in
cytoskeleton remodeling, cell proliferation, survival and migration (Mills and Moolenaar
2003). As depicted in Fig. 1. 2, a major difference in G protein coupling between the Edg
LPA1-3 receptors and the novel non-Edg LPA4-6 receptors is that LPA1-3 couple to Gi but
not Gs while LPA4-6 couple to Gs instead of Gi. Gs is linked to activation of adenylyl
cyclase (AC) and intracellular cAMP. In contrast, Gi inhibits adenylyl AC and decreased
cAMP and activates the Ras/MAPK cascade and the PI3K-Akt pathway through subunit
released from Gi (Anliker and Chun 2004, Radeff-Huang et al 2004, Van Leeuwen et al
2003). Gq is linked to activation of phospholipase C (PLC), which, in turn, catalyzes
hydrolysis of phosphatidylinositol biphosphate (PIP2) to diacylglycerol (DAG) to
activate protein kinase C (PKC) and inositol trisphosphate (IP3) to trigger intracellular
calcium mobilization (Fukushima and Chun 2001). Activation of G12/13, which directly
binds to the Rho-specific guanine nucleotide exchange factor p115RhoGEF, leads to
activation of the Rho-ROCK pathway (Kranenburg et al 1999, Ren et al 1999) that
regulates actomyosin-driven cytoskeleton contraction and cell shape changes (Bar-Sagi
and Hall 2000).
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Figure 1.2. LPA receptors and G protein signaling cascades.

1.1.3 LPA and cell proliferation
The role of LPA as a growth factor was initially shown in fibroblasts. The
mitogenic activity of LPA has now been demonstrated in several cell lineages including
normal and transformed epithelial cells, endothelial cells, smooth muscle cells,
astrocytes, and renal mesangial cells (Radeff-Huang et al 2004, Van Leeuwen et al 2003).
The mitogenic activity of LPA is sensitive to pertussis toxin (Fang et al 2000b, Van
Corven et al 1989, van Corven et al 1992), implicating a Gi-dependent mechanism in
LPA-mediated cell proliferation. The Gi-induced inhibition of intracellular cAMP may be
a partial but not the sole stimulus of LPA-induced cell proliferation (Van Corven et al
1989). Similar to the mitogenesis driven by peptide growth factors, the Ras/ERK and
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PI3K/Akt pathways are essential for LPA-induced cell growth (Cook and McCormick
1996, Fang et al 2000b, Kranenburg and Moolenaar 2001). Active Erk translocates to the
nucleus to activate expression of proliferation-associated genes. The dependence on PI3K
of LPA-induced cell proliferation may relate to the prominent anti-apoptotic activity of
the PI3K-Akt pathway (Kennedy et al 1997).

Due to the critical role of Gi-dependent signals in LPA-driven cell proliferation,
the Edg LPA receptors seem to be major receptor subtypes to activate mitogenic program
although the possibility of inputs from non-Edg LPA receptors cannot be excluded.
However, most cell lines express more than one Edg LPA receptor, making it difficult to
link a proliferative response to a specific receptor subtype. In a few earlier studies,
ectopic expression of the LPA1 receptor supports LPA-dependent DNA synthesis in B103
cells (Fukushima et al 1998) and cellular survival in Schwann cells (Li et al 2003, Weiner
and Chun 1999). In MEFs, deletion of LPA1 or LPA2 does not significantly affect
proliferative response to LPA. However, simultaneous disruption of LPA1 and LPA2
strongly inhibited LPA-induced cell proliferation (Contos et al 2002), suggesting the
functional redundancy between the two LPA receptors in mediating growth response of
MEFs to LPA. In malignant cells particularly colon cancer cells, accumulating evidence
indicate that LPA2 mediates mitogenic signals. LPA2 stimulates expression of a large
number of cell cycle promoters or regulators such as c-Myc, cyclin D1, HIF1α, and
Krüppel-like factor 5 (Fang et al 2004, Hu et al 2001, Mori et al 2009, Yang et al 2005).
The ability of LPA2 to promote proliferation of malignant cells is consistent with its
overexpression in many types of cancer and its recognized function as an oncogene.
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The ultimate biological responses to LPA vary from one cell type to another,
likely as a result of the types and expression levels of the LPA receptors as well as
possible crosstalk with other families of cell surface receptors. LPA transactivation of
receptor tyrosine kinases such as EGFR, PDGFR and c-met occurs in a panel of cancer
cell lines (Goppelt-Struebe et al 2000, Oyesanya et al 2010, Zhao et al 2007). This crosscommunication may provide a permissive signal in combination with other G protein
effectors to elicit cellular responses to LPA including cell proliferation.

1.1.4 LPA and cell motility
LPA stimulation of tumor cell invasion was first shown in 1993 (Imamura et al
1993). However, this biological activity of LPA was not well appreciated until the tumor
cell motility-stimulating factor ATX was identified to be lysoPLD accounting for LPA
production in the blood (Umezu-Goto et al 2002). ATX has long been known as a large
protein secreted by melanoma and other cancer cells to enhance tumor cell migration and
invasion through a GPCR-mediated mechanism (Stracke et al 1992). It is now well
established that ATX stimulates tumor cell motility through formation and action of LPA.
The migratory effect of LPA and the underlying mechanism of action have
become a subject of extensive recent studies in the area of LPA biology. It is now well
known that LPA activates cell motility through G12/13-mediated activation of RhoA and
Gi-PI3K-mediated activation of Rac. These small Rho GTPases regulate cell detachment
and forward movement in a coordinate manner (Etienne-Manneville and Hall 2002).
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Precisely, RhoA mediates cell contraction through activation of ROCK which
phosphorylates myosin light chain (MLC) and thereby induces actomyosin-based
contractility and cell rounding (Kimura et al 1996). On the other hand, LPA activates Rac
through a Gi, PI3K and guanine nucleotide exchange factor Tiam1 (Van Leeuwen et al
2003) or SOS1/EPS8/ABl1 tri-complex (Chen et al 2010).
Using LPA1-/- skin fibroblasts, Hama et al provided compelling evidence that
LPA1 is essential for both LPA- and ATX-induced cell migration of fibroblasts (Hama et
al 2004). Independent studies in the Rh7777 hepatoma cells (Umezu-Goto et al 2002) and
the B103 neuroblastoma cells (Van Leeuwen et al 2003) devoid of functional LPA
receptors indicated that ectopic expression of LPA1 is sufficient to restore migratory
responses to LPA. The importance of LPA1 in LPA-dependent cell migration has been
further confirmed in cancer cells of colon, breast (Chen et al 2007, Shida et al 2003), and
stomach (Shida et al 2004a). Despite the primary role of LPA1 in the migratory response
to LPA, there has been also evidence for participation or auxiliary role of LPA2 and even
LPA3 in LPA regulation of cell motility. However, it remains unknown whether LPA2 or
LPA3 alone in the absence of LPA1 is sufficient to initiate the migratory response to LPA.
It is possible that in certain cellular contexts, these other LPA receptors could cooperate
with LPA1 to enhance or sustain migratory signals such as Rac activation. In contrast to
the Edg LPA receptors, the non-Edg LPA receptors do not couple to Gi and Gi-dependent
migratory signals. Instead, we have recently shown that using LPA4 wild type and null
MEFs, the LPA4 receptor negatively regulates cell motility, likely through overactivation of the G12/13-Rho pathway to deregulate the ratio of Rac and Rho (Lee et al
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2008). Appropriate balance of Rac and Rho activities plays a pivotal role in coordinating
cellular migratory responses to various motogens.

1.2 TGFβ
1.2.1 TGFβ production and activation
TGFβ (refers to TGFβ1 in TGFβ family), is a polypeptide member of the TGFβ
super family of cytokines. It is ubiquitously expressed in human adult tissues, and
dramatically increased in almost all cancer cell lines (Wu et al 2009). TGFβ expression is
regulated

at

multiple

levels,

including

transcription,

mRNA

stability,

and

posttranslational processing. Van Obberghen-Schilling et al have shown that TGFβ
positively regulates its own expression in normal and transformed cells (Van ObberghenSchilling et al 1988). In cancer cells, v-src was reported to transcriptionally activate
TGFβ through AP-1 (Birchenall-Roberts et al 1990). In tumor microenvironment, TGFβ
is also produced by infiltrated immune cells including dendritic cells, natural killer cells
and natural regulatory T cells (Flavell et al 2010).
TGFβ is synthesized as a precursor molecule containing a propeptide region in
addition to the TGFβ monomer (Derynck et al 1985). TGFβ is secreted to the
extracellular matrix (ECM) in a latent complex consisting of the TGFβ dimer, latency
associated peptide (LAP) dimer and latent TGFβ-binding protein (LTBP) (Rifkin 2005).
This complex is called large latent complex (LLC). After its secretion, the LLC remains
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in the ECM in the inactivated form. It will be further processed to release the active
TGFβ homodimer (Annes et al 2003).
TGFβ can be activated in either integrin-dependent or integrin-independent
manner. Matrix metalloproteinases (MMPs), such as MMP9 and MMP2 (Yu and
Stamenkovic 2000), acidic pH (Lyons et al 1988), reactive oxygen species (ROS)
(Barcellos-Hoff and Dix 1996) and thrombospondin-1 (TSP-1) (Schultz-Cherry and
Murphy-Ullrich 1993) have all been shown to stimulate the release of TGFβ from the
latent form. The αV integrins can activate TGFβ by binding to the RGD motif of LAP
and induce a change in the conformation of the latent complex to liberate/activate TGFβ
from its latent complex, thereby allowing access of the mature TGFβ to the TGFβ
receptors (TβRs) and induction of classic TGFβ signaling (Munger et al 1999). On the
other hand, αV integrins also can create a close connection between the latent TGFβ
complex and MMPs (Mu et al 2002), a process similar to the mechanism for integrin
interaction with ATX to localize LPA production from LPC in platelets (Fulkerson et al
2011).

1.2.2 TGFβ signaling
After release as a homodimer, TGFβ binds to type II receptor (TβRII), leading to
formation of a receptor complex and phosphorylation of the TβRI. After being
phosphorylated and activated, the type I receptor subsequently phosphorylates a receptorregulated SMAD (R-Smad), allowing complex formation of R-Smad with Smad4 (coSmad) and translocation to the nucleus where the Smad complex associates with a DNA-
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binding partner and binds to specific DNA region of TGFβ target genes to activate or
repress transcription (Massague 1998).
TGFβ activation of TβRI and TβRII not only triggers activation of the Smad
pathway as stated above but also induces activation of other Smad-independent signaling
cascades by the kinase activities of the TβRs. Rapid activation of MAPK pathways,
including Erk, JNK and p38 MAPK occurs in a Smad-independent manner in TGFβ
challenged cells (Derynck and Zhang 2003). In addition, TGFβ treatment rapidly
activates Rho GTPases, including RhoA, Cdc42, and Rac. As mentioned earlier, the
activation of these small GTPases causes membrane ruffling and formation of stress
fibers and lamellipodia. Thus TGFβ could induce changes in cell morphology, promotion
of cell motility, and epithelial to mesenchymal transition (EMT) (Zavadil et al 2001).

1.2.3 Complexity and regulation of the TGFβ-Smad pathway
Receptors of ligands of the TGFβ superfamily are characterized with a highly
conserved intracellular serine-threonine kinase domain (Liu et al 2001). There are two
functional classes of receptors for TGFβ superfamily ligands: type II and type I, which
are encoded by five and seven genes in human genome, respectively (Schmierer and Hill
2007). Binding of ligand recruits the pre-formed dimers of TβRII and TβRI to form
heterotetrameric receptor complex (Sasaki et al 2003). The TβRII kinase is thought to be
constitutively active and phosphorylates the TβRI at several serine and threonine residues
in a glycine and serine rich domain (GS domain) which is strictly conserved in all type I
TβRs. Phosphorylation of the GS-domain enables recruitment of R-Smads: Smad1,
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Smad2, Smad3, Smad5 and Smad8. Smad2 and Smad3 are phosphorylated and activated
by TGFβ while Smad1, Smad5 and Smad8 are phosphorylated/activated by bone
morphogenetic protein (BMP) signal. R-Smads and Smad4 share two highly conserved
domains, MH1 and MH2. Except for Smad2, which cannot bind DNA directly (Yagi et al
1999), the MH1 domains of other R-Smads and Smad4 are capable of DNA binding. The
MH2 domain mediates Smad-receptor interactions, Smad-Smad interactions and Smad
interactions with other transcription factors, co-activators or co-repressors (Schmierer and
Hill 2007).
Negative feedback in TGFβ signaling pathway is mediated by induction of the
inhibitory Smads (I-Smads) Smad6 and Smad7. I-Smads also contain the MH2 domain
which has been proposed to bind to R-Smads and form heterotrimmers to block their
abilities to induce or repress expression of target genes (Zhang et al 2007). Other studies
demonstrated the interaction of I-Smads with TβRI, causing competitive inhibition of RSmad binding (Hayashi et al 1997). As an indirect mechanisms, Smad7 interacts
constitutively with the HECT-domain E3 ubiquitin ligases SMURF1 and SMURF2 and
targets them to the activated receptors, which leads to degradation of the active TβRs
(Ebisawa et al 2001, Kavsak et al 2000, Ogunjimi et al 2005). Smad7 also interacts with
GADD34, a regulatory subunit of protein phosphtase-1 (PP1), therefore targeting the
catalytic subunit of PP1 to activated TβR for dephosphorylation and inactivation (Shi et
al 2004).
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The I-Smads are not the only inhibitory mediators of the TGFβ-Smad pathway.
The Smad binding elements (SBEs) are not necessarily unoccupied in the absence of
TGFβ signal. The proto-oncoproteins SKI and SKI-related novel protein N (SnoN) bind
the same repeated elements (GTCTAGAC) as the Smad3/4 complex and are thought to
bind in conjunction with Smad4 (Stroschein et al 1999). TGFβ signaling causes rapid
degradation of SnoN, and to a lesser extent SKI, allowing the Smad3/4 complex to
displace SKI and SnoN from SBEs (Stroschein et al 1999). SKI and SnoN have been
shown to be overexpressed in multiple cancers. Therefore, the suppression of TGFβ
signal transduction by overexpressed SKI and SnoN may contribute to tumorigenesis
(Reed et al 2005).

1.2.4 Cytostatic response genes of TGFβ
The role of TGFβ in inducing cytostasis in normal epithelial cells is well
characterized. In TGFβ-treated cells, TGFβ induces rapid and sustained expression of two
cyclin-dependent kinase (CDK) inhibitors, p21Waf1 and p15Ink4b. Moreover, TGFβ
downregulates expression of c-Myc, Id1 and Id2, three transcription factors involved in
promotion of proliferation and inhibition of differentiation (Siegel and Massague 2003).
As a general mode of TGFβ regulation of gene expression, the Smad3-Smad4 complex
binds to a DNA-binding cofactor which further lands on the gene promoter and regulates
transcription. As illustrated in Figure 1.3, in the case of p21Waf1, upon stimulation with
TGFβ, phosphorylated Smad3, Smad4 and transcription factor FoxO form an activator
complex that binds to a specific region of the p21Waf1 gene promoter to initiate
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transcription (Seoane et al 2004). In addition, the Smad complex can interact with the
Sp1 transcription factor to activate the p21Waf1 gene promoter (Pardali et al 2000).
Transcription of p15Ink4b gene is also induced by binding of a Smad to the p15Ink4b gene
promoter. However, the co-factor(s) for p15Ink4b induction by TGFβ has not been
identified yet (Seoane et al 2001). TGFβ downregulation of c-Myc is mediated by a
Smads-E2F4/5-p107 complex. Upon binding to the c-Myc promoter, the pocket protein
p107 within the inhibitory complex recruits HDAC that functions as a transcriptional
repressor (Chen et al 2002). The transcriptional repression of Id1 by TGFβ requires a
Smads-ATF3 complex binding to the Id1 promoter (Kang et al 2003). The SBE site and
ATF3 element on the Id1 promoter are not clustered but instead set apart by 18 base pairs.
Among the target genes of TGFβ-mediated repression, Id2 is the only one not directly
repressed by a Smad complex. Id2 is transcriptionally activated by c-Myc-Max, hence
downregulation of c-Myc expression by TGFβ prevents Id2 transcription (Lasorella et al
2000).
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Figure 1.3. The TGFβ cytostatic program in epithelial cells. Adapted from
Seoane et al “Escaping from the TGFβ anti-proliferative control”
Carcinogenesis (2006) 27 (11): 2148-2156.

1.3 Crosstalk between LPA and TGFβ
A number of previous studies suggest that LPA indirectly interacts with TGFβ
signaling and functionality. For example, LPA induces expression and secretion of TGFβ
in human corneal fibroblasts (Jeon et al 2012). In human mesenchymal stem cells, LPA
induces their differentiation into myofibroblast-like cells in an autocrine TβR-Smaddependent manner (Jeon et al 2008). In keratinocytes, LPA acts as a growth inhibitor
instead of stimulator. Sauer et al reported that LPA transactivates Samd3 of the TGFβ
signaling pathway to exert such a cytostatic effect (Sauer et al 2004). Activation of latent

20

TGFβ is the rate-limiting step in TGFβ bioavailability. Recent evidence suggests that
LPA could also participate in the process of TGFβ activation from its latent precursor
(Xu et al 2009). Xu et al. showed that LPA stimulates αVβ6 integrin dependent activation
of TGFβ in epithelial cells via the LPA2 receptor, RhoA and ROCK (Xu et al 2009). In
airway smooth muscle cells, LPA induces TGFβ activation via the integrin αVβ5 (Tatler
et al 2011). Studies of genetic mouse models have implicated the LPA1 receptor in the
development of lung and renal fibrosis (Pradere et al 2008, Tager et al 2008).
Accumulating evidence suggests that LPA interacts with TGFβ signaling to stimulate
expression of the pro-fibrotic connective tissue growth factor (CTGF) (Cabello-Verrugio
et al 2011, Gan et al 2011, Pradere et al 2007, Vial et al 2008). Taken together, these
investigations indicate that LPA regulates TGFβ expression, activation, secretion or
signaling, which may be relevant to diverse physiological and pathophysiological
processes in mammalian cells.
On the other hand, there is little information on whether TGFβ may crosscommunicate with LPA signal transduction to influence cellular functions, especially in
epithelial carcinoma cells. As stated earlier, TGFβ and LPA are co-present at elevated
levels in tumor microenvironments. The known biological effects of TGFβ and LPA on
carcinoma cells are opposite or overlapping. In this dissertation project, I utilized breast
and ovarian cancer cells as model systems to study combinatory effects of TGFβ and
LPA on two major cellular processes of cancer: growth and motility. These studies
showed novel and interesting biological outcomes of LPA and TGFβ co-treatment of
breast and ovarian cancer cells and the underlying mechanisms. As described in chapter 2,
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we identified LPA-induced expression of the cyclin dependent kinase inhibitor p21 as an
indispensable component of the TGFβ-mediated cytostasis. TGFβ alone induced p21
expression weakly in TGFβ-sensitive cells. LPA cooperated with TGFβ to elicit the
maximal p21 induction. Mechanistically, LPA stimulated p21 via LPA1 and LPA2
receptors and Erk-dependent activation of the CCAAT/enhancer-binding protein beta
(C/EBPβ) transcription factor. When we examined the simultaneous effects of TGFβ and
LPA on tumor cell motility in Chapter 3, we found that TGFβ signaling via a Smaddependent pathway inhibits activity of the LPA1 gene promoter, LPA1 mRNA
transcription and LPA1-dependent migration and invasion of breast and ovarian cancer
cells. Further characterization using multiple molecular approaches showed that LPA1 is a
physiological target gene of TGFβ-mediated repression involving a specific TBE element
on the LPA1 promoter. The work represents the first detailed study of transcriptional
regulation of an LPA receptor.
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CHAPTER 2

LYSOPHOSPHATIDIC ACID–INDUCED P21WAF1 EXPRESSION MEDIATES
THE CYTOSTATIC RESPONSE OF BREAST AND OVARIAN CANCER CELLS
TO TRANSFORMING GROWTH FACTOR BETA

Part of the work presented in this Chapter has been published in Molecular Cancer
Research 9(11): 1562-70, 2011

2.0 Abstract
Lysophosphatidic acid (LPA) is a multifunctional intercellular phospholipid
mediator presents in blood and other biological fluids. In cancer cells, LPA stimulates
expression or activity of inflammatory cytokines, angiogenic factors, matrix
metalloproteinases, and other oncogenic proteins. In this study, we showed that LPA
upregulated expression of the cyclin-dependent kinase inhibitor p21Waf1 in TGFβsensitive breast and ovarian cancer cells, but not in TGFβ-resistant cells. We examined
the possibility that LPA-induced p21 might contribute to the cytostatic response to TGFβ.
In serum-free conditions, TGFβ alone induced p21 expression weakly in TGFβ-sensitive
cells. Serum or serum-borne LPA cooperated with TGFβ to elicit the maximal p21
induction. LPA stimulated p21 via LPA1 and LPA2 receptors and Erk-dependent
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activation of the CCAAT/enhancer binding protein beta transcription factor independent
of p53. Loss or gain of p21 expression led to a shift between TGFβ-sensitive and resistant phenotypes in breast and ovarian cancer cells, indicating that p21 is a key
determinant of the growth inhibitory activity of TGFβ. Our results reveal a novel crosstalk between LPA and TGFβ that underlies TGFβ-sensitive and -resistant phenotypes of
breast and ovarian cancer cells.

2.1 Introduction
LPA is a naturally occurring intercellular mediator of diverse biological processes
including neurogenesis, angiogenesis, would healing, immunity, and carcinogenesis
(Panupinthu et al 2010). LPA is produced by activated platelets during coagulation and
thus is a normal constituent of serum (Eichholtz et al 1993, Sano et al 2002). LPA is a
ligand of at least six G protein-coupled receptors (GPCRs) (Choi et al 2010). The
LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7 receptors are members of the endothelial
differentiation gene (Edg) family, sharing 50-57% homology in their amino acid
sequences. GPR23/P2Y9/LPA4 of the purinergic receptor family and the related
GPR92/LPA5 and P2Y5/LPA6 have been identified as additional LPA receptors, which
are structurally distinct from the LPA1-3 receptors (Choi et al 2010). The LPA receptors
couple to multiple G proteins, Gq, Gi, G12/13 and Gs, which, in turn, activate diverse
pathways including Gq-mediated stimulation of phospholipase C (Fukushima and Chun
2001), Gi-mediated activation of the Ras-MAPK and PI3K (Takeda et al 1999), and
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G12/13-mediated activation of RhoA (Kranenburg et al 1999). Activation and integration
of these signaling events downstream of LPA receptors leads to cytoskeleton remodeling,
cell proliferation, survival, and migration (Mills and Moolenaar 2003). Recent studies
demonstrated that LPA exerts its biological actions through transcriptional activation of
multiple target genes involved in a wide range of physiological and pathophysiological
processes (Teo et al 2009).
TGFβ is also a platelet-derived factor that controls a multitude of biological
activities including cell proliferation (Huang and Huang 2005), differentiation (Fei and
Chen 2010), and apoptosis (Perlman et al 2001). The complicated role of TGFβ is
mediated through the heteromeric complex of transmembrane serine/threonine kinases,
the type I and type II receptors (TβRI and TβRII), and the Smad family of transcription
factors and non-Smad signaling pathways (de Caestecker et al 2000, Derynck and Zhang
2003). TGFβ inhibits proliferation of epithelial cells and thus plays a role in early tumor
suppression. However, TGFβ frequently fails to induce growth arrest in transformed
epithelial cells. On the other hand, TGFβ stimulates migration and invasion of neoplastic
cells, thereby promoting the metastatic potentials of advanced cancer (Bierie and Moses
2006, Massague 2008).
The anti-proliferative effect of TGFβ is mediated by a complex signaling network
involving TβRI and TβRII activation of Smad2/3 and ultimately transcriptional
modulation of growth control genes such as induction of the cyclin-dependent kinase
(CDK) inhibitors p21Waf1 and p15Ink4b, and suppression of the c-Myc, Id1 and Id2
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transcription factors (Siegel and Massague 2003). Cancer cells tend to escape from the
anti-proliferative effect of TGFβ through acquisition of mutations in components of the
TGFβ signal transduction pathway or through deregulation of other signaling cascades
interconnecting with the TGFβ pathway (Derynck et al 2001). Mutations in the TβRII
receptor gene (Siegel and Massague 2003) as well as mis-sense mutation or deletion of
Smad2 and Samd4 (Sjoblom et al 2006, Yang and Yang 2010) have been identified in
different types of cancer. There is also evidence for overexpression of oncoproteins in
inactivation of the cytostatic effect of TGFβ in cancer, such as Myc-Miz-1 complex
(Seoane et al 2001), Evi-1 (Kim and Letterio 2003), FoxG1 (Seoane et al 2004), CDK
(Matsuura et al 2004) and Ski and/or SnoN (Zhang et al 2003). However, these
aberrations seen in only fractions of human tumors do not explain the generally altered
responses to TGFβ in a wide spectrum of cancers.
In the present study, we examined the potential crosstalk between LPA signaling
and TGFβ in growth regulation of breast and ovarian cancer cells. We report that LPA
up-regulates expression of the CDK inhibitor p21 in breast and ovarian cancer cells
sensitive to TGFβ- induced growth arrest but not in TGFβ-resistant cancer cells. In
TGFβ-sensitive cells, LPA cooperates with TGFβ to elicit the maximal induction of p21
to mediate the cytostatic response to TGFβ. Loss or gain of p21 expression led to a shift
between TGFβ sensitive and resistant phenotypes in these cells. Our results reveal a novel
mechanism underlying the cytostatic program of TGFβ in breast and ovarian cancer cells.
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2.2 Materials and Methods
Materials Anti-phospho C/EBPβ, phospho-Erk1/2, tubulin α/β antibodies and PD98059
were obtained from Cell Signaling (Danvers, MA). Anti-C/EBPβ, p21, and Erk
antibodies were from Santa Cruz Biotech (Santa Cruz, CA). LPA (1-oleoly, 18:1) and
S1P were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Prior to use, LPA and
S1P were dissolved in PBS containing 0.5% fatty acid-free bovine serum albumin (BSA)
obtained from Roche (Indianapolis, IN). TGFβ was obtained from PeproTech Inc (Rocky
Hill, NJ). TPA was from Sigma (St Louis, MI). Fetal bovine serum (FBS) was obtained
from Atlanta Biological (Atlanta, GA). Oligonucleotides were synthesized by Operon
Biotechnologies, Inc. (Huntsville, AL). TRIzol and cell culture reagents were obtained
from Invitrogen Inc. (Carlsbad, CA). The transfection reagent Dharmafect 1 was obtained
from Dharmacon (Lafayette, CO). Plasmid DNA was purified using the endo-free
purification kit from Qiagen (Valencia, CA).

Cell Culture MDA-MB-231 was provided by S Spiegel (Virginia Commonwealth
University). SK-BR-3 and BT-549 were obtained from Dr. G. Mills (MD Anderson
Cancer Center). MDA-MB-231 cells were maintained in Dulbecco modified Eagle
medium (DMEM) with 10% FBS and antibiotics (100 U/ml penicillin and 100 µg/ml
streptomycin). Other breast and ovarian cancer cell lines used in the study were cultured
in RPMI 1640 supplemented with 10% FBS and antibiotics as we described previously
(Fang et al 2004).
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Western blotting Cells were lysed in SDS sample buffer or in ice-cold X-100 lysis
buffer [1% Triton X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1
mM EGTA, 10% glycerol, 100 mM NaF, 10 mM Na PPi, and protease inhibitor cocktail].
Total cellular proteins were resolved by SDS-PAGE, transferred to Immun-Blot
membrane [poly(vinylidene difluoride)] from BIO-RAD (Hercules, CA), and
immunoblotted

with

antibodies

following

the

protocols

of

manufacturers.

Immunocomplexes were visualized with an enhanced chemiluminescence detection kit
from Amersham (Piscataway, NJ).

siRNA knockdown The siRNA oligos for LPA receptors (LPA1 #4050, LPA2 #44997,
LPA3 #136436 and LPA5 #s32725), p21 (#S415) and C/EBPβ (#s2891) were obtained
from Applied Biosystems (Carlsbad, CA). siRNA oligos for Erk (Erk1 #L-003592-00 and
Erk2 #L-03555-00) were obtained from Dharmacon (Lafayette, CO). They were
transfected into cells using Dharmafect 1 following the manufacturers’ protocol. In brief,
cells were plated in 6-well plates to reach 50% confluence before transfection for 12-16
hours with specific siRNA (100 pmole) and Dhamafect 1 (4 µL). The transfected cells
were cultured in complete medium for approximately 48 hours before experiments.
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Quantitative PCR Total cellular RNA was isolated using Trizol (Invitrogen).
Complementary DNA (cDNA) was synthesized from RNA (1 µg, random primers) using
the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems. The
relative levels of individual LPA receptors were determined using gene specific probes,
the TaqMan Universal PCR Master Mix and the 7900HT Fast Real-Time PCR System
(Applied Biosystems).

Statistics All numerical data were presented as mean ±SD from at least 3 independent
experiments. The statistical significance of differences was analyzed using Student's t test
where p<0.05 was considered statistically significant.

2.3 Results

2.3.1 Induction of p21 by LPA in TGFβ-sensitive breast and ovarian cancer cells
It has been well documented that LPA regulates expression of cytokines,
angiogenic factors and many other proteins involved in tumorigenesis and cancer
metastasis (Fang et al 2004, Oyesanya et al 2008, Song et al 2009). In contrast to these
oncogenic mediators, we also found that in a subset of breast and ovarian cancer cell lines,
LPA up-regulates expression of p21, an inducible inhibitor of CDKs. As shown in Fig.
2.1A, in the MDA-MB-231 breast carcinoma cells and the Caov-3 ovarian carcinoma
cells, LPA stimulated p21 expression in a time-dependent manner. Following addition of
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10 µM LPA to serum-starved cells, p21 protein was induced at 1 hour. The p21 protein
levels reached the maximum by 4 hours. Similarly, LPA also induced upregulation of p21
mRNA in these two cell lines (Fig. 2.1B).

Figure 2.1. LPA-induction of p21 in TGFβ-sensitive breast and ovarian cancer cells.
A. MDA-MB-231 cells and Caov-3 cells were starved in serum-free medium and
treated with LPA (10 µM) for the indicated periods of time. The cells were lysed with
SDS sample buffer and expression of p21 protein was examined by immunoblotting.
B. MDA-MB-231 cells and Caov-3 cells were treated with LPA (10 μM) for 1 hour.
Cells were lysed with TRIzol and RNA was isolated as described in Materials and
Methods. The p21 mRNA levels were normalized to the untreated sample (untreated
sample as 1). In this and following figures, data is presented as mean ± SD, the
statistical significances of the data were indicated with * if p<0.05, or ** if p<0.01.

The p21 protein inhibits activity of cyclin-CDK2 or cyclin-CDK4 complexes to
block cell cycle progression at G1 phase (Brugarolas et al 1999). In addition, p21 can
bind to proliferating cell nuclear antigen thereby blocking DNA synthesis (Waga et al
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1994). Paradoxically, p21 has been also reported to stabilize interactions between
CDK4/CKD6 and D-cyclins thus promoting the formation of active complexes in a
concentration-dependent manner (Giacinti and Giordano 2006). Although modest levels
of p21 may promote assembly of active cyclin-CDK complex (Cheng et al 1999),
excessive expression of p21 generally causes cell cycle arrest. In our hands, the induction
of p21 by LPA was not associated with growth inhibition. Instead, LPA treatment led to
increased proliferation in MDA-MB-231 and Caov-3 cells (see Fig. 2.8) as well as in
other breast and ovarian cancer cell lines in which LPA did not trigger p21 expression
(Fig. 2.2).

Figure 2.2. Correlation between LPA-mediated p21 induction and sensitivity to TGFβ
mediated cytostasis. Various breast and ovarian cancer cell lines in 6-well plates were
incubated for 48 hours in complete medium with or without TGFβ (2.5 ng/ml). Cell
numbers were quantified with a Coulter counter. The induction of p21 protein by LPA
in these cell lines was examined by immunoblotting as described in Fig. 2.1.
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In an effort to understand the biological significance of LPA-mediated p21
induction, we noticed surprisingly that LPA stimulated p21 expression only in cell lines
sensitive to the TGFβ-induced growth arrest but not in cells refractory to TGFβ. As
demonstrated in Fig. 2.2, treatment of MDA-MB-231 and Caov-3 cells with TGFβ (2.5
ng/ml) for 48 hours resulted in a significant decrease in cell numbers compared to control
cells cultured in the absence of TGFβ. In contrast, TGFβ did not inhibit the growth of cell
lines such as BT-549, SK-BR-3, OVCA-432 and SKOV-3 in which LPA did not induce
p21 (Fig. 2.2).

2.3.2 Correlation of LPA and TGFβ induction of p21
We next explored the possibility that LPA-driven p21 expression modulates the
sensitivity of breast and ovarian cancer cells to TGFβ. Coincidently, the effect of TGFβ
on p21 expression was identical to that of LPA in these breast and ovarian cancer cells.
As shown in Fig. 2.3, TGFβ induced p21 expression at significant levels only in MDAMB-231 and Caov-3 cells but not in TGFβ-resistant lines in which LPA failed to induce
p21 (Fig. 2.3).

32

Figure 2.3. p21 induction was only found in TGFβ sensitive cells. Breast and ovarian
cancer cell lines in complete medium were treated for 6 hours with or without TGFβ
(2.5 ng/ml) before lysis with SDS sample buffer. Expression of p21 protein and
phosphorylated Smad3 was analyzed by immunoblotting.

The loss of p21 inducibility by TGFβ could be due to abnormalities in TGFβ
receptors or the TGFβ intracellular signaling through Smads. It is well known that TGFβ
superfamily ligands bind to a TβRII, which recruits and phosphorylates a TβRI. TβRI
then phosphorylates receptor-regulated Smads (R-Smad) such as Smad2 and Smad3,
which then bind to the common mediator Smad (co-Smad). R-Smad forms heterodimeric
complexes with co-Smads and accumulates in the nucleus where the complexes
participate in regulation of TGFβ target genes involved in growth control (Siegel and
Massague 2003). As shown in Fig. 2.3, TGFβ induced phosphorylation of Smad3 in all
breast and ovarian cancer cell lines examined, irrespective of their status of TGFβ
sensitivity. To further confirm the presence of the intact TGFβ signaling in these cells, we
examined TGFβ induction of another TGFβ target gene Plasminogen activator inhibitor-1
(PAI-1). Upon treatment of TGFβ, all cell lines showed increased expression of PAI-1
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mRNA (Fig. 2.4). This suggests that both TGFβ-sensitive and resistant cells maintain
functional TGFβ receptors and the Smad3 signal transducer.

Figure 2.4. Induction of TGFβ target gene PAI-1 in resistant cells.
Breast and ovarian cancer cell lines in complete medium were treated
for 2 hours with or without TGFβ (2.5 ng/ml) before lysis with TRIzol.
PAI-1 mRNA level was determined by qPCR using TaqMan probe.

2.3.3 Input of LPA signaling in TGFβ-induced p21 expression
Because phosphorylation of Smad3 by TGFβ was observed in both TGFβsensitive and resistant cells, p21 induction by TGFβ seems to involve signaling routes
other than the canonical Smad pathway in these cells. In addition, both MDA-MB-231
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and Caov-3 carry mutant p53 (Hui et al 2006, Yaginuma and Westphal 1992). TGFβinduced p21 expression in these cells is apparently mediated by a p53-independent
process. We therefore examined the possibility that LPA contributes to TGFβ-induced
p21 expression in the TGFβ-sensitive MDA-MB-231 and Caov-3 cells. When these cells
were cultured in serum-free medium, TGFβ stimulated only weak to modest levels of p21
(Fig. 2.5A). The maximal p21 induction by TGFβ was seen when the cells were
incubated in complete medium containing FBS (Fig. 2.5A), a condition in which the
effects of TGFβ on cell proliferation and p21 expression were assessed in earlier
experiments (Fig. 2.2). Serum itself induced p21 expression in MDA-MB-231 and Caov3 cells. This suggests that induction of p21 by TGFβ that we had observed resulted from
a combined action of TGFβ and a co-factor present in serum.
LPA is a prominent serum-borne factor responsible for many biological activities
of serum (Moolenaar 1999). To determine whether LPA reproduces the action of serum
in concert with TGFβ to maximize p21 induction, we examined the effect of LPA and
TGFβ on p21 expression in MDA-MB-231 and Caov-3 cells. Indeed, p21 induction was
maximized when both LPA and TGFβ were present (Fig. 2.5B). We also assessed other
serum factors such as sphingosine 1 phosphate (S1P) and insulin for their ability to
regulate p21 expression (Hiromura et al 2002, Kim et al 2004). In contrast to LPA, S1P
and insulin did not increase p21 expression. Nor did S1P and insulin potentiate the effect
of TGFβ on p21. Taken together, these results suggest that a significant input of TGFβinduced p21 is attributable to the action of LPA, which likely underlies the sensitivity of
breast and ovarian cancer cells to TGFβ.
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Figure 2.5. Input of LPA action in TGFβ-mediated p21 induction. A. MDA-MB-231
and Caov-3 cells were serum starved and stimulated for 6 hours with TGFβ (2.5
ng/ml), FBS (5%), or TGFβ+FBS. Expression of p21 in these cells was assessed by
immunoblotting. B. MDA-MB-231 and Caov-3 cells were treated and analyzed as
described in A except that FBS was replaced with LPA (10 µM).

2.3.4 Role of p21 in mediating the cytostatic response to TGFβ
To confirm an essential role for p21 in mediating the TGFβ response, we used
siRNA to knockdown p21 expression in the TGFβ sensitive MDA-MB-231 and Caov-3
cells. As shown in Fig. 2.6A, suppression of p21 induction by siRNA converted these
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cells into a resistant phenotype. The p21 knockdown cells became insensitive to the
inhibitory effect of TGFβ, confirming that p21 induction is indeed a key component of
TGFβ-induced cytostasis in breast and ovarian cancer cells.
If the p21 inducibility distinguishes TGFβ-sensitive cells from resistant ones, we
assume that the resistant cells could be rendered sensitive to TGFβ when p21 is induced
somehow by other p21 stimuli. To test this possibility, we took advantage of the fact that
phorbol ester (12-O-tetradecanoylphorbol-13-acetate, TPA) induces expression of p21 in
cancer cells (Salabat et al 2006). We treated the TGFβ-resistant cell lines with TGFβ
alone or TGFβ and TPA (0.1 µM). The presence of TPA led to induction of high and
sustained expression of p21 while the cells treated with TGFβ alone did not show p21
expression (Fig.2.6B). Treatment with TPA was not associated with inhibition of cell
proliferation as shown in Fig. 2.6B, suggesting that p21 induced by TPA was not
sufficient to affect cell growth without TGFβ. However, the presence of TPA-induced
p21 expression enables TGFβ to suppress growth of these otherwise TGFβ-resistant cells,
consistent with the importance of p21 in mediating TGFβ sensitivity (Fig. 2.6B). To
confirm that the growth inhibitory effect was due to the presence of p21 not the apoptotic
effect of TPA, we performed annexin V staining on TGFβ or TGFβ+TPA treated BT-549
and OVCA-432 cells. No significant increase of apoptosis was observed with the
presence of TPA (Fig. 2.7).
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Figure 2.6. Essential role of p21 in the cytostatic response to TGFβ. A. The TGFβsensitive cells lost sensitivity to TGFβ following siRNA knockdown of p21
expression. MDA-MB-231 and Caov-3 cells in 6-well plates were transfected with
control or p21 siRNA. The cells were treated for 48 hours with or without TGFβ (2.5
ng/ml) before quantification of cell numbers with a Coulter counter. Efficiency of p21
siRNA knockdown was confirmed by immunoblotting. B. TGFβ resistant cell lines
gained sensitivity to TGFβ following TPA induction of p21. BT-549 and OVCA-432
in 6-well plates were treated for 48 hours with or without TGFβ in the presence of
TPA (0.1 µM) or vehicle before quantification of cell numbers. Expression of p21 in
these cells treated with TGFβ, TPA or TGFβ+TPA was analyzed by immunoblotting.
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Figure 2.7. TPA treatment has no effect in cell apoptosis. BT-549 and OVCA-432
cells treated with TGFβ or TPA+TGFβ for 48 hours. Cells were analyzed for apoptosis
using vibrant Apoptosis Kit #3 (Invitrogen) to stain apoptotic cells with fluorescenceconjugated Annexin V.

2.3.5 p21-dependent inhibition of LPA-driven cell proliferation by TGFβ
LPA stimulated p21 expression in MDA-MB-231 and Caov-3 cells (Fig. 2.5B).
However, in spite of the robust and sustained induction of p21, LPA is mitogenic towards
these cells. To determine whether TGFβ is able to block the mitogenic effect of LPA, we
compared the growth of MDA-MB-231 and Caov-3 cells incubated with LPA in the
absence or presence of TGFβ. Fig. 2.8A shows that TGFβ effectively inhibits cell number
increases stimulated by LPA. Moreover, siRNA knockdown of p21 expression resulted in
resistance of these cells to TGFβ (Fig. 2.8B), confirming an essential role for p21 in
TGFβ repression of LPA-induced cell proliferation. In TGFβ-resistant breast and ovarian
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cancer cell lines, LPA also acted as a mitogen. The mitogenic activity of LPA, however,
was not affected by TGFβ, consistent with the lack of induction of p21 by LPA, TGFβ or
LPA and TGFβ in these cells.
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Figure 2.8. p21-dependent inhibition of LPA-induced cell proliferation by TGFβ. A.
TGFβ inhibits LPA-afforded cell proliferation. MDA-MB-231 and Caov-3 cells in 6well plates were incubated with LPA (10 µM) or vehicle (BSA) in the presence or
absence of TGFβ (2.5 ng/ml). B. The growth inhibitory effect of TGFβ depends on
p21 induction. MDA-MB-231 and Caov-3 cells were transfected with control or p21
siRNA as described in Figure 4. The cells were treated with LPA in the presence or
absence of TGFβ. The cell numbers presented in both panels were determined after 48
hours. Efficiency of p21 siRNA knockdown in transfected cells was analyzed by
immunoblotting as shown in Fig. 2.5A.
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2.3.6 Mechanisms for LPA induction of p21
Ovarian and breast cancer cells express multiple LPA receptors including LPA1,
LPA2, LPA3 and LPA5 as described previously (Fang et al 2002, Finak et al 2008, Liu et
al 2009). Expression of the LPA4 and LPA6 receptors was very low in the breast and
ovarian cancer lines. We thus used siRNA to knockdown expression of LPA1, LPA2,
LPA3 or LPA5. The cells treated with LPA were then examined for p21 protein
expression. LPA-induced p21 was drastically reduced by downregulation of LPA1 or
LPA2 (Fig. 2.9). Knockdown of LPA3 or LPA5 did not attenuate the effect of LPA on p21
expression. Therefore, we conclude that LPA-stimulated p21 expression in MDA-MB231 and Caov-3 cells occurs through the LPA1 and LPA2 receptors.
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Figure 2.9. LPA1 and LPA2 are responsible for LPA stimulation of p21. MDA-MB231 and Caov-3 cells were transfected with specific siRNA for LPA1-3, LPA5 or nontarget control siRNA. The cells were serum starved and stimulated with LPA (10 µM)
before immunoblotting analysis of p21 protein expression. The efficiency of
knockdown of individual LPA receptors was examined by RT and quantitative PCR as
described in Materials and Methods. The mRNA levels of LPA receptors were
presented as percentages relative to those in the control siRNA-transfected cells
(defined as 100%).

LPA induced strong and sustained activation of Erk in MDA-MB-231 and Caov-3
cells (Fig. 2.10) (Du et al 2010, Oyesanya et al 2010). When Erk1 and Erk2 were silenced
by siRNAs, LPA induction of p21 was blocked (Fig. 2.10A), indicating that the Erk
pathway is linked to activation of p21 expression in response to LPA. In contrast to Erk,
PI3K was dispensable for LPA-induced p21 induction because its inhibitor LY-294002
did not attenuate the effect of LPA on p21 expression.
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Erk couples directly or indirectly to diverse downstream effectors and
transcription factors that could culminate in p21 expression. We used siRNA to screen for
transcription factors required for LPA-induced p21 expression including AP-1, Sp1, NFκB and C/EBPβ. In this group of transcription factors, C/EBPβ was found to be critical to
the p21 induction. Knockdown of C/EBPβ expression prevented LPA-induced p21
expression (Fig. 2.10B). Finally, inhibition of Erk activity with the MEK inhibitor
PD98059 prevented C/EBPβ phosphorylation and the subsequent p21 induction in LPAtreated MDA-MB-231 and Caov-3 cells (Fig. 2.10C). These findings demonstrate that
LPA stimulates p21 expression through the LPA1/2-Erk-C/EBPβ signaling network.
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Figure 2.10. Induction of p21 by LPA through the LPA1/LPA2-Erk-C/EBPβ pathway.
A. Knockdown of Erk1/2 blocks LPA induction of p21. MDA-MB-231 and Caov-3
cells were transfected with Erk siRNAs or non-target control siRNA. The cells were
stimulated for 6 hours with LPA (10 µM) followed by immunoblotting analysis of
p21, Erk and tubulin proteins. B. C/EBPβ was critical for LPA induction of p21.
MDA-MB-231 and Caov-3 cells were transfected with control or C/EBPβ siRNA. The
transfected cells were treated for 6 hours with LPA and analyzed for p21 and C/EBPβ
protein expression. C. MDA-MB-231 and Caov-3 cells were serum starved and then
treated with LPA (10 µM) in the presence of PD98059 (30 µM) or vehicle (DMSO).
PD98059 was added 1 hour before LPA. Cells were then lysed at indicated time
points. Levels of phospho-Erk1/2, p21 and phospho-C/EBPβ were examined by
immunoblotting.
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2.4 Discussion
TGFβ-mediated cytostasis is induced, at least in part by Smad-dependent
activation of TGFβ target genes involved in cell cycle control, primarily CDK inhibitors
p15, p21 and p27. In addition, TGFβ activation of Smad represses expression of proteins
that promotes cell cycle progression including c-Myc, Id1, Id2, E2F, and Sp-1 (Feng et al
2000, Massague 2004). These TGFβ-induced cytostatic transcriptional programs,
however, are subverted in a majority of cancers, leading to cytostatic resistance to TGFβ
(Barcellos-Hoff and Ewan 2000). In addition to genetic and epigenetic aberrations in
TGFβ receptors or Smad proteins, emerging data suggests that in most malignancies,
abrogation of TGFβ-induced growth arrest is mediated by abnormal expression or
function of intracellular proteins implicated in Smad regulation of its target genes
(Massague 2008). In theory, environmental cues that influence expression or activity of
Smad, Smad regulatory circuits or Smad responsive genes could also alter cellular
responses to TGFβ. However, there have been few studies to analyze potential crosstalk
between extracellular factors such as LPA and TGFβ-Smad to regulate the
responsiveness of cancer cells to TGFβ.
Using breast and ovarian cancer cells as a model system, we demonstrated that
LPA upregulates expression of the prototype Smad target gene p21, contributing to the
TGFβ-mediated growth inhibition. The conclusions were summarized as a model shown
in Fig. 2.11. In these cells, the ability of LPA to stimulate p21 expression correlated well
with TGFβ induction of p21 and the cytostatic effect of TGFβ. By means of induction
and suppression of p21 expression in TGFβ-resistant and sensitive cells, we could reverse
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the cellular responses to TGFβ confirming an essential role of p21 in mediating the
cytostatic response to TGFβ. Previous studies in breast and ovarian cancer cells also
supported the involvement of p21 as a key mediator of TGFβ-induced growth inhibition
(Massague 2004).

Figure 2.11. Working model: LPA induced p21 mediates response of breast and
ovarian cancer cells to TGFβ. Induction of p21 from the LPA1/2-ERK-C/EBPβ
pathway is required for cells to respond to TGFβ mediated cytostasis. P: phosphate,
yellow oval: Smad3, blue oval: Smad4.
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Another observation in ovarian cancer indicates that abrogation of TGFβ induced
growth arrest is associated with overexpression of FoxG1, a negative regulator of p21
expression (Chan et al 2008). Therefore, p21 seems to be a general mediator of TGFβinduced growth arrest in multiple types of cancer cells. The findings of the present work
highlight the possibility that the sensitivity to TGFβ in breast and ovarian cancer cells
could be reconstituted through upregulation of p21 expression. It will be of interest to
develop and test agents that can specifically activate p21 expression or stabilize p21
protein in cancer cells.
An interesting finding in the current study is that p21 induction in TGFβ sensitive
cells is accomplished through cooperative effects of TGFβ and the serum-borne factor
LPA. A significant input of p21 expression is evoked from LPA activation of its
receptors, namely LPA1 and LPA2. Using molecular and pharmacological approaches, we
further demonstrated that LPA upregulates p21 expression in TGFβ responsive cells
through the Erk-C/EBPβ signaling pathway. We have previously shown that C/EBPβ is a
transcription factor activated by LPA which accounts for LPA-induced expression of
Cox-2 and sphingosine kinase 1 in various cancer cells (Oyesanya et al 2008,
Ramachandran et al 2010). The results in the present work links C/EBPβ to the induction
of p21 by LPA in TGFβ growth arrest program in breast and ovarian cancer cells,
suggesting a general role for this transcription factor in regulation of LPA target genes.
Consistent with their resistance to TGFβ, the stimulatory effect of LPA on p21 was not
seen in most breast and ovarian cancer cell lines. The differential effects of LPA on p21
in different cell lines are not fully understood but could be due to distinct expression
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patterns of LPA receptors in these cells. The receptor knockdown experiments in the
TGFβ-sensitive MDA-MB-231 and Caov-3 cells indicated that both LPA1 and LPA2
receptors are required for induction of p21 by LPA. Among the TGFβ-resistant cell lines,
SKOV-3 and BT-549 express low levels of LPA2 (Chen et al 2007, Fang et al 2004) and
OVCA-432 exhibits elevated LPA3 (Fang et al 2004). It is conceivable that co-expression
of two or more receptors at appropriate levels is important for optimal induction of p21
by LPA. Alternatively, it is also possible that certain LPA receptors including the
conventional LPA3, novel LPA receptor subtypes and other unknown LPA receptors
could be present in the resistant cells and function as negative regulators of certain
biological functions of LPA.
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CHAPTER 3

THE LYSOPHOSPHATIDIC ACID RECEPTOR 1 IS A NOVEL TARGET GENE
OF TRANSFORMING GROWTH FACTOR BETA

3.0 Abstract
LPA1/Edg2 is the first identified LPA receptor. Although its wide tissue
distribution and biological functions have been well studied, little is known about how
LPA1 is transcriptionally regulated. In this part of my dissertation, I showed that LPA1 is a
physiological target of transforming growth factor beta (TGFβ)-mediated repression. In
both normal and neoplastic cells, TGFβ inhibits LPA1 promoter activity, LPA1 mRNA
expression, and LPA1-dependent chemotaxis and tumor cell invasion. Knockdown of the
TGFβ intracellular effector Smad3 or Smad4 with lentivirally transduced shRNA relieved
these inhibitory effects of TGFβ. Interestingly, the LPA1 promoter contains two potential
TGFβ inhibitory elements (TIEs), each consisting of a Smad binding site and an adjacent
E2F4/5 element, structurally similar to the TIE found on the promoter of the well-defined
TGFβ target gene c-Myc. Deletion and point mutation analysis indicate that the distal TIE
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located at 401 bp from the transcription initiation site, is required for TGFβ repression of
the LPA1 promoter. A DNA pull-down assay showed that the -401 TIE was capable of
binding Samd3 and E2F4/5 in TGFβ-treated cells. The binding of the Smad complex to
the native -401 TIE sequence of the LPA1 gene promoter was further verified by
chromatin immunoprecipitation assays. We therefore identified a novel role of TGFβ in
the control of LPA1 expression and LPA1-coupled biological functions, adding LPA1 to
the list of TGFβ-repressed target genes.

3.1 Introduction
LPA is a naturally occurring intercellular mediator of diverse biological processes
including neurogenesis, angiogenesis, wound healing, immunity, and carcinogenesis
(Panupinthu et al 2010). LPA is produced by activated platelets during coagulation and
thus is a normal constituent of serum (Sano et al 2002). LPA is a ligand of multiple G
protein-coupled receptors (GPCRs) (Fukushima and Chun 2001). The LPA1/Edg2,
LPA2/Edg4 and LPA3/Edg7 receptors are members of the endothelial differentiation gene
(Edg) family, sharing 50-57% homology in their amino acid sequences. In addition to the
Edg LPA1-3 receptors, GPR23/P2Y9/LPA4 of the purinergic receptor family, the related
GPR92/LPA5, and P2Y5/LPA6 have been reported to be additional LPA receptors
(Fukushima and Chun 2001).
LPA1 is expressed in most adult tissues and in embryonic cells. Only minor
abnormalities such as craniofacial dysmorphism and defective sucking behavior were
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found in lpa1-deficient mice (Contos et al 2000a). However, more recent studies of lpa1
null mice subjected to various pathophysiological conditions revealed that LPA1 is
involved in initiation of neuropathic pain (Inoue et al 2004), embryonic and adult
neurogenesis and promotion of pulmonary and renal fibrosis (Pradere et al 2007, Tager et
al 2008). Some of these biological functions of LPA1 are attributed to the motilitystimulating activity of LPA in mammalian cells. Substantial evidence indicates that LPA1
is the primary LPA receptor subtype to mediate LPA-dependent chemotaxis and tumor
cell invasion. In contrast to the LPA2 receptor that is commonly overexpressed in various
cancers, gene expression profiling studies failed to show any consensus increase in LPA1
expression between normal and malignant cells (Hendrix et al 2006, Radvanyi et al 2005,
Sanchez-Carbayo et al 2006, Skrzypczak et al 2010, Su et al 2007). Instead, some
expression profiling or array analyses suggest decreases in LPA1 mRNA expression in
various malignancies (Hendrix et al 2006, Sanchez-Carbayo et al 2006, Shida et al 2004b,
Skrzypczak et al 2010, Su et al 2007).
More intriguingly, several groups recently reported that LPA1 expression is
repressed by Nm23 (Horak et al 2007b, Marshall et al 2010). Nm23 is the first identified
metastasis suppressor gene that, by definition, inhibits the process of metastasis but not
growth of primary tumors (Marshall et al 2010). In human breast carcinomas, LPA1
expression inversely correlated with that of Nm23 (Horak et al 2007b). However, little is
known about how Nm23 represses LPA1. Furthermore, there is no evidence that LPA1
expression is elevated in metastatic cancer compared to primary tumors. Thus, LPA1
expression is apparently controlled by complex regulatory mechanisms involving other
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unrecognized activators or repressors. In the present study, we showed for the first time
that TGFβ, a platelet-derived cytokine co-present with LPA in the circulation and tumor
microenvironments, represses LPA1 gene transcription and LPA1-dependent motilitystimulating activity via a TGFβ inhibitory element (TIE) containing both Smad and
E2F4/5 binding sites on the LPA1 gene promoter. These results represent a novel form of
crosstalk between TGFβ and LPA signaling.

3.2 Materials and Methods
Materials LPA (1-oleoly, 18:1) was obtained from Avanti Polar Lipids, Inc. (Alabaster,
AL). Prior to use, LPA was dissolved in PBS containing 0.5% fatty acid-free bovine
serum albumin (BSA) obtained from Roche (Indianapolis, IN). TGFβ was obtained from
PeproTech Inc (Rocky Hill, NJ). Anti-Smad3 and Smad4 antibodies were from Abcam
(Cambridge, MA). Tubulin α/β antibody was obtained from Cell Signaling (Danvers,
MA). Anti-E2F4 antibody was from Santa Cruz Biotech (Santa Cruz, CA). FBS was
obtained from Atlanta Biological (Atlanta, GA). All primers were synthesized by Operon
Biotechnologies, Inc. (Huntsville, AL). Biotinylated dsDNA were synthesized by IDT
(Coralville, IA). TRIzol and cell culture reagents were obtained from Invitrogen Inc.
(Carlsbad, CA). Reverse transcription kit, TaqMan gene expression assays, SYBR Green
PCR mix and QPCR master mix were obtained from Applied Biosystems (Carlsbad, CA).
The transfection reagent LT1 was obtained from Mirus (Madison, WI). Plasmid DNA
was purified using the endo-free purification kit from Qiagen (Valencia, CA).
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Cell Culture MDA-MB-231 was provided by Dr. S Spiegel (Virginia Commonwealth
University) and was maintained in Dulbecco modified Eagle medium (DMEM) with 10%
FBS and 100 U/ml penicillin and 100 µg/ml streptomycin). IOSE-29 was originally
obtained from Dr. N. Auersperg (University of British Columbia, Canada) and cultured
as described previously (Auersperg et al 1994). Primary Mammary epithelial cells (10018) and primary ovarian epithelial cells (NOE-71) were provided by Dr. Y. Yu (MD
Anderson Cancer Center) and were cultured in HuMEC Ready Medium (Invitrogen) and
50:50 M199/F12 medium with 10% FBS, 20 ng/ml EGF and gentamicin (10 µg/ml),
respectively. MCF-10A was provided by Dr. D. Gewirtz (Virginia Commonwealth
University) and kept in DMEM/F12 medium with 5% horse serum, 10 μg/ml insulin, 20
ng/ml EGF, 100 ng/ml cholera toxin and 0.5 μg/ml hydrocortisone. Other cancer cell
lines used in the study were cultured in RPMI 1640 supplemented with 10% FBS and
antibiotics as we described previously (Fang et al 2004).

Migration and invasion assays Cell migration was measured using the Transwell
chambers (Costar, Corning, NY). Transwell were coated with 10 µg/ml Type I collagen
and placed in the lower chamber containing serum-free medium supplemented with
vehicle, TGFβ, LPA or LPA+TGFβ. Cells suspended in serum-free medium containing
0.01% fatty acid-free BSA were added to the upper chamber at 2 × 104 cells/well. Cells
were allowed to migrate for 6 hours at 37°C. Non-migrated cells were removed from the
top filter surface with a cotton swab. Migrated cells attached to the underside of the
Transwell were washed with PBS and stained with crystal violet and counted under a
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microscope. The invasion of tumor cell lines was measured using the growth factor–
reduced Matrigel invasion chambers (BD Biosciences, San Jose, CA). The assays were
performed as migration assays except that the cells were incubated for 20 hours.

shRNA short hairpin RNA (shRNA)-expressing lentivirus constructs were generated
using pLV-RNAi vector (Biosettia, San Diego, CA). The Smad3 target sequences
(Smad3sh1

GTGA-CCACCAGATGAACCA

(Blount

et

al

2008),

Smad3sh2

GGATTGAGCTGCACCTGAATG (Jazag et al 2005) and Smad4 target sequences
(Smad4sh1 GCAGGTGGCTGGTCGGAAA (Giampieri et al 2009), Smad4sh2
GCCAGCTACTTACCATCATA (Deckers et al 2006)) were inserted to the pLV-RNAi
plasmid following the manufacturer’s protocol. The LPA1 shRNA plasmids were
obtained from Dr. S. Huang (Medical College of Georgia). The shRNA lentiviruses were
propagated in 293FT cells. The culture supernatants were used to infect cancer cell lines.
The GFP-positive cells were sorted out using flow cytometer proximately a week after
virus infection.

Quantitative PCR (qPCR) Total cellular RNA was isolated using Trizol (Invitrogen).
Complementary DNA (cDNA) was synthesized from RNA (1 µg, random primers) using
the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems. The
relative levels of individual LPA receptors were determined using gene specific probes,
the TaqMan Universal PCR Master Mix and the 7900HT Prism Real-Time PCR System
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(Applied Biosystems).

Luciferase vectors, deletion, and site-directed mutagenesis The luciferase reporter
vector pGL2-LPA1-Luc containing -1156 to +86 was generated by PCR amplification of
the

LPA1

promoter

sequence

(forward

5’-GCACTCGAGTGCAAAGCT-

ACACTGGGAAA-3’, reverse 5’-GCAAAGCTTCACACTCTCACTGGCACTCG-3’).
The PCR product was inserted into pGL2-Basic-Luc at XhoI and HindIII sites. The
deletion mutant (-366 to +86) was made by PCR amplification of the fragment from
pGL2-LPA1-Luc (forward 5’-GCACTCGAGCTGACGCTCCCTGAGTGG-3’, reverse
5’-GCAAAGCTTCACACTCTC-ACTGGCACTCG-3’) and re-inserted into the pGL2Basic-Luc at the XhoI and HindIII sites. The promoter sequences in these plasmids were
verified by automatic sequencing. The -401 and -40 TIE consensus sites within pGLLPA1-Luc were converted into inactive sequences by site-directed mutagenesis. The wild
type -401 TIE 5’-GGCTTTGGCGCG and wide type -40 TIE 5’-GGCTTCGCGC were
converted into 5’-GGCTAATTCGCGC and 5’-GGCAATTCGCC, respectively. For
luciferase assays, MDA-MB-231 and SKOV-3 were transfected with luciferase vectors
using TransIT-LT1 (Mirus Bio). About 48 to 60 hours after transfection, the cells were
treated with TGFβ or vehicle for 16-20 hours. Cell extracts were prepared and assayed
for luciferase activity using the luciferase assay kit from Promega.

DNA pull-down assay Lysates of MDA-MB-231 and SKOV-3 cells were prepared by
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brief sonication in the HKMG buffer (10 mM, Tris-HCl, pH 7.9, 100 mM KCl, 5 mM
MgCl2, 10% glycerol, 1 mM DTT, 0.1% NP40 and protease inhibitors) using the Fisher
Scientific Sonic Dismembrator Model 100, followed by 10 minutes of centrifugation at
12,000 × g at 4 °C. Cellular proteins (400 µg) were incubated with 4 µg of biotinylated
double-stranded

oligonucleotides

(5’-CCCTACTGCCCGGCTTTGGCGCGCTGG-

CAGGAGGAG–biotin) for 16 hours at 4 °C. The M-280 Streptavidin Dynabeads
(Invitrogen) (30 µl) were added to each sample and incubated for another hour at 4 °C.
The Dynabeads were washed three times with PBS before western analysis of Smad3 or
E2F4.

Chromatin immunoprecipitation (ChIP) assay TGFβ or vehicle-treated MDA-MB-231
and SKOV-3 cells were cross-linked with 1% formaldehyde for 10 minutes at room
temperature. The cells were lysed for 10 minutes in ice-cold lysis buffer (5 mM HEPES,
pH 8.0, 80 mM KCl, 1% NP40 and protease inhibitors). The nuclear fraction that was
recovered by centrifugation (5 minutes at 5000 × g) was resuspended in a ChIP assay
buffer (50 mM HEPES, pH 8.0, 10 mM EDTA, 1% SDS, and protease inhibitors) and
sonicated on ice to achieve an average chromatin length of 200-1000 bp. The sonicated
samples were pre-cleared by incubation with Protein G Dynabeads (Invitrogen). The
material recovered from the equivalent of 106 cells was incubated for 16 hours at 4 °C
with 2 μg of either normal rabbit IgG (Santa Cruz), anti-Smad3, Smad4 or E2F4
antibodies. Protein G Dynabeads were added and incubated for 2 hours. The DNA-
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protein-beads mixes were washed sequentially once with a low salt buffer (20 mM Tris,
pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton 100), once with a high salt
buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton 100),
once with LiCl buffer (10 mM Tris-HCl, pH 8.0, 0,25 M LiCl, 1 mM EDTA, 1%
deoxycholate, 1% NP-40), and finally twice with TE buffer (10 mM Tris-HCl, pH 8, 1
mM EDTA). The specifically bound complexes were eluted from the Protein G
Dynabeads by incubation twice for 15 minutes at 65 °C with TE elution buffer (10
mM Tris-HCl, pH 8, 1 mM EDTA, 1% SDS). The immunoprecipitated complexes and
the starting material (input) were incubated overnight at 65 °C to reverse crosslinking,
then treated with RNase A followed by proteinase K and purified using the QIAquick
Spin Columns (Qiagen, Valencia, CA). The DNA samples were recovered in 100 μL H2O,
and analyzed by qPCR using SYBR Green. Details of the primer used for qPCR were
listed in Table 3.1.

Table 3.1. Primers used in ChIP assays
5’-GTGCTACGTGGAACAAGCAG-3’
-401 Forward
5’-GGCGGGACAGTGTGAGC-3’
-401 Reverse
5’-AGCGAGCGCAGGTAAGG-3’
-40 Forward
5’-GCACCCACACTCTCACTGG-3’
-40 Reverse
c-Myc TIE Forward 5’-TTATAATGCGAGGGTCTGGA-3’
5’-TGCCTCTCGCTGGAATTACT-3’
c-Myc TIE Reverse

Statistics All numerical data were presented as mean ±SD from at least 3 independent
experiments. The statistical significance of differences was analyzed using Student's t test
where p<0.05 was considered statistically significant.
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3.3 Results

3.3.1 TGFβ inhibits expression of LPA1
Previous studies showed that LPA stimulates production and release of TGFβ (Xu
et al 2009), transactivates the intracellular effectors of TGFβ (Sauer et al 2004) or
cooperates with TGFβ to regulate gene expression (Wu et al 2011). However, little is
known about whether TGFβ communicates with LPA signal transduction to modify
cellular responses to the multi-functional LPA. To explore this possibility, we treated the
MDA-MB-231 breast carcinoma cell line and the SKOV-3 ovarian carcinoma cell line
with TGFβ for 3 or 6 hours, and monitored changes in mRNA expression of LPA
signaling molecules including various LPA receptors. Interestingly, the treatment resulted
in 67% and 48% decreases in LPA1 mRNA levels in MDA-MB-231 and SKOV-3,
respectively, as analyzed by RT and qPCR (Fig. 3.1A). TGFβ did not decrease expression
of other known LPA receptors in these cells (Fig. 3.1B)
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Figure 3.1. TGFβ inhibits expression of LPA1 mRNA. A. MDA-MB-231 and SKOV3 cells were cultured with TGFβ (2.5 ng/ml) for 3 and 6 hours. LPA1 mRNA levels
were examined by RT and qPCR as described in Materials and Methods. The mRNA
levels of LPA1 in TGFβ treated cells were presented as percentages relative to those in
untreated control cells (defined as 100%). B. MDA-MB-231 and SKOV-3 cells were
treated with TGFβ (2.5 ng/ml) for 6 hours, LPA1, LPA2 and LPA3 mRNA levels were
examined using specific TaqMan probes as described in A.

To generalize the observation of the inhibitory effect of TGFβ on LPA1, we
examined a panel of breast, ovarian and other cancer cell lines, including BT-549, Caov-3
and DOV-13. Treatment with TGFβ induced 30-67% decreases in LPA1 mRNA levels in
these cell lines (Fig. 3.2A). Most of the cancer cell lines such as SK-BR-3, BT-549,
SKOV-3 and DOV-13 were resistant to the growth inhibitory effect of TGFβ as we
reported recently (Wu et al 2011). Thus, the inhibition of LPA1 expression by TGFβ was
independent of the cytostatic program of TGFβ. In addition, TGFβ also downregulated
expression of LPA1 in normal primary and immortalized epithelial cells such as primary
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mammary epithelial cells (1001-8), primary ovarian epithelial cells (NOE-71),
immortalized breast epithelial cell line MCF-10A, and immortalized ovarian surface
epithelial cell line IOSE-29 (Fig. 3.2A). The only exception to the negative regulation by
TGFβ was the DLD1 colon cell line. DLD1 was deficient in TβRII as reported previously
(Markowitz et al 1995) and as evidenced by the inability of TGFβ to induce Smad3
phosphorylation in this particular line (Fig. 3.2B). It is also worth noting that LPA1 was
highly expressed in DLD1 cells (Lee et al 2008, Shida et al 2003), likely as a result of the
absence of TGFβ-mediated repression.

Figure 3.2. TGFβ inhibits expression of LPA1 mRNA in all cancer cells with intact
TGFβ pathway. A. Multiple cancer cell lines, immortalized breast (MCF-10A) and
ovarian (IOSE-29) epithelial cell lines, primary mammary (1001-8) and ovarian
(NOE71) epithelial cells were treated for 6 hours with TGFβ (2.5 ng/ml) and analyzed
for LPA1 mRNA expression as in Fig.3.1. C. All cell lines and primary cells were
treated with TGFβ (2.5 ng/ml) for 1 hour before lysis with SDS sample buffer and
immunoblotting analysis of Smad3 phosphorylated at Ser423/425.
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3.3.2 TGFβ attenuates LPA1-dependent cell migration and invasion
Since TGFβ represses LPA1 expression, we anticipated that TGFβ would
attenuate LPA1-dependent actions of LPA. Although each of the Edg-family LPA
receptors may contribute to promoting cell motility in certain cellular contexts,
substantial evidence supports an essential and probably sufficient role for LPA1 in driving
random migration, chemotaxis and tumor cell invasion (Hama et al 2004, Shida et al
2003, Van Leeuwen et al 2003). In breast and ovarian cancer cell lines that we examined
(MDA-MB-231, SKOV-3, and DOV-13), LPA stimulated a robust chemotactic response
as analyzed by the transwell assay (Fig. 3.3A). LPA also promoted invasion of these cells
through Matrigel (Fig. 3.3B).

62

Figure 3.3. TGFβ attenuates LPA1-dependent cell migration and invasion. A. The
chemotactic responses to TGFβ (2.5 ng/ml), LPA (5 μM), or LPA+TGFβ in the breast
cancer cell line MDA-MB-231, and the ovarian cancer cell lines SKOV-3 and DOV13 were measured by transwell chambers. The cells (2 x 104 cells/well) were loaded to
the upper wells and allowed to migrate for 6 hours. The migrated cells on the
underside of the Transwell were stained with crystal violet, counted under a
microscope and presented as numbers of cells/well. B. Cell invasion induced by TGFβ
(2.5 ng/ml), LPA (5 μM), or LPA+TGFβ in MDA-MB-231, SKOV-3 and DOV-13
cells was measured with the growth factor–reduced Matrigel invasion chambers. The
experiment was performed as the migration assay in A except that the cells were
allowed to invade for 20 hours.
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In agreement with the crucial role of LPA1 in stimulation of cell motility, shRNA
knockdown of the LPA1 receptor expression or pharmacological inhibition of LPA1 with
Ki16425 blocked LPA-induced chemotaxis (Fig. 3.4A and B). On the other hand, TGFβ
only weakly increased migration of MDA-MB-231, SKOV-3 and DOV-13 cells (Fig.
3.3). This trend of increase in chemotactic migration towards TGFβ was not statistically
significant. However, TGFβ was capable of stimulating modest but significant increases
in invasion of SKOV-3 and DOV-13 cells (Fig. 3.3B). The ability of TGFβ to stimulate
invasion of breast and ovarian cancer cell lines was much weaker than that of the potent
motogen LPA.
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Figure 3.4. Important role of LPA1 in mediating LPA induced cell migration. A.
Expression of LPA1 in MDA-MB-231 and SKOV-3 cells was silenced with
lentivirally transduced shRNA. The chemotactic migration of these stable knockdown
cells and control cells induced by LPA (5 μM) was analyzed as described in Figure
3.3A. D. LPA-induced migration of MDA-MB-231 and SKOV-3 cells was analyzed in
the presence or absence of the LPA1/LPA3 specific antagonist Ki16425 (Ki) (10 μM).
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When MDA-MB-231, SKOV-3 and Dov-13 cells were co-stimulated with both
LPA and TGFβ, TGFβ significantly inhibited LPA stimulation of migration and invasion.
We observed 30-50% decreases in migration and 60-80% decreases in invasion in the
presence of LPA and TGFβ compared to the effects of LPA alone. Moreover, when pretreated MDA-MB-231 and SKOV-3 cells with 2.5 ng/ml TGFβ for 6 hours to achieve the
downregulation of LPA1, followed by migration (Fig. 3.5A) and invasion (Fig. 3.5B)
assay only using LPA as motogen, we observed similar reductions in cell migration and
invasion comparing with vehicle treated control cells. In all cell lines we examined, the
TGFβ mediated inhibition of invasion was more prominent than the effect of TGFβ on
migration. This was likely due to the longer incubation of the cells with TGFβ during the
invasion experiments. These data demonstrated that TGFβ repression of LPA1 expression
was sufficient to impair LPA1-dependent cell migration and invasion.
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Figure 3.5. TGFβ pre-treatment attenuates LPA1-dependent cell migration and
invasion. A. MDA-MB-231 and SKOV-3 cells were treated with TGFβ (2.5 ng/ml) for
6 hours. LPA (5 μM) was used to induce migration. Migration assays were performed
as described in Figure 3.3. B. TGFβ (2.5 ng/ml) pre-treated cell invasion induced by
LPA (5 μM) in MDA-MB-231 and SKOV-3 was measured with the growth factor–
reduced Matrigel invasion chambers. The experiment was performed as the migration
assay in A except that the cells were allowed to invade for 20 hours.
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3.3.3 TGFβ represses LPA1 expression and LPA1-dependent cell migration and
invasion in a Smad-dependent manner
Upon binding of TGFβ to its receptors, both Smad-dependent and Smadindependent pathways are activated by the kinase activity of TβRs (Derynck and Zhang
2003). Regulatory Smads (RSmads), such as Smad2 and Smad3, are phosphorylated by
TβRs, and form heterodimers with the co-Smad, Smad4, to translocate to the nucleus
where the Smad complex regulates transcription of target genes (Massague et al 2005). In
addition, TGFβ activates TβR-associated proteins and other intracellular signaling
pathways such as MAPK, PP2A/p70S6K, RhoA and TAK1/MEKK1 to elicit Smadindependent responses to TGFβ (Seoane 2006). To elucidate the mechanism underlying
TGFβ repression of LPA1, we examined the possibility for the participation of the Smaddependent pathway in the process. To this end, we first knocked down Smad3 expression
in MDA-MB-231 and SKOV-3 cells using lentivirally transduced shRNA. Smad3, but
not Smad2, was reported to be the R-Smad involved in binding to TIE to downregulate
TGFβ target genes, most notably c-Myc (Chen et al 2002). Expression of Smad3 protein
was efficiently silenced by Smad3 shRNA in these cell lines (Fig. 3.6A). The silencing of
Smad3 expression eliminated the inhibitory effect of TGFβ on expression of LPA1 (Fig.
3.6B).
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Figure 3.6. TGFβ represses LPA1 in a Smad3-dependent manner. A. Expression of
Smad3 in MDA-MB-231 and SKOV-3 cells was silenced with lentivirally transduced
shRNA. The Smad3 protein levels in shRNA knockdown cells and control shRNA
transduced cells were examined by immunoblotting. B. Smad3 shRNA and control
shRNA-transduced MDA-MB-231 and SKOV-3 cells were treated with or without
TGFβ (2.5 ng/ml) for 6 hours prior to RT and qPCR analysis of LPA1 mRNA levels.

To determine the role of Smad3 in TGFβ repression of LPA-driven cell motility,
we performed migration and invasion assays in these cells. In Smad3 knockdown cells,
TGFβ no longer inhibited LPA-driven cell migration (Fig. 3.7A) or invasion (Fig. 3.7B).
These results suggest a Smad3-dependent mechanism to control LPA1 expression and
LPA1-linked migration and invasion. In further support of this, Smad3 knockdown was
accompanied by considerable increases in basal LPA1 mRNA levels (Fig. 3.6B) as well
as in basal and LPA-induced cell migration and invasion (Fig. 3.7A and B). Likewise,
shRNA knockdown of the co-Smad, Smad4 in these cells abrogated the inhibitory effects
of TGFβ on LPA1 mRNA expression and LPA1-dependent cell migration (Fig. 3.8).
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Figure 3.7. Knockdown of Smad3 abolished the inhibitory effect of TGFβ in LPAinduced cell motility. LPA-mediated chemotactic migration (A) and invasion (B) of
control and Smad3 knockdown MDA-MB-231 and SKOV-3 cells were analyzed in
the absence or presence of TGFβ (2.5 ng/ml). Data was presented as described in Fig
3.3.
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Figure 3.8. Knockdown of Smad4 abolished the inhibitory effect of TGFβ in LPAinduced cell motility. A. Smad4 knockdown efficiency was analyzed with
immunoblotting. B. Smad4 shRNA and control shRNA-transduced cells were treated
with or without TGFβ (2.5 ng/ml) for 6 hours prior to RT and qPCR analysis of LPA 1
mRNA levels. C. LPA-mediated chemotactic migration of control and Smad4
knockdown cells were analyzed in the absence or presence of TGFβ (2.5 ng/ml). Data
was presented as described in Fig 3.3.

3.3.4 The LPA1 gene promoter contains two potential TIEs
The TGFβ-Smad pathway both activates and represses gene transcription. There
is a long list of TGFβ activated targets such as type I collagen and the cyclin-dependent
kinase inhibitors p21Waf1 and p15Ink4b. Conversely, only a few TGFβ-repressed genes
have been well defined with c-Myc and Id1 being the best characterized. As mentioned in
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Chapter 1, the co-repressors for two TGFβ target genes c-Myc and Id1 have been
identified. In the case of c-Myc, Smad3 forms a complex with E2F4/5-p107 in the cytosol
and translocates into nucleus with Smad4 when Smad3 is phosphorylated by the active
TβRs (Chen et al 2002). The complex binds to a Smad binding element right next to an
E2F binding site. For inhibition of Id1, the co-repressor ATF3 binds with Smads in the
nucleus, consequently the repressor complex binds to a Smad binding element adjacent to
a CREB binding site (Kang et al 2003).
Analysis of the human LPA1 gene promoter sequences revealed the presence of
two potential TIEs, one located at -401 (designated -401 TIE) and the other at -40
(designated -40 TIE) from the transcription initiation site (see sequence details in Fig.
3.9A). The composite TIE consisting of Smad and E2F4/5 binding sites was present only
in the LPA1 gene promoter but not in the promoters of other LPA receptors (LPA2-6).
Between these two TIEs, there are also an SBE (-324 GTCT -321) and a possible ATF
site (-348 TGACGCTC -341) with 5 out of 8 nucleotides matching with the ATF
consensus sequence (TGACGTCA).

3.3.4 TGFβ represses the transcriptional activity of the LPA1 gene promoter
In an effort to identify the co-repressor for the TGFβ-Smad pathway to control
LPA1 expression, we cloned a 1242-bp fragment of the LPA1 gene promoter (-1156 to
+86) into pGL2-Basic-Luc vector to construct pGL2-LPA1-Luc. MDA-MB-231 and
SKOV-3 cells were transfected with pGL2-LPA1-Luc and cultured with or without TGFβ
for 16 hours before measurement of luciferase activity in cell lysates. TGFβ treatment
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resulted in a modest but consistent decrease in luciferase activity (Fig. 3.9B). Deletion of
the proximal -401 TIE (named del in Fig. 3.9B) at -366 abolished the negative effect of
TGFβ on the LPA1 promoter-driven luciferase activity (Fig. 3.9B), suggesting that the
deleted sequence containing the -401 TIE rather than the potential SBE-ATF3 or the
further downstream -40 TIE is the major site for TGFβ repression of LPA1 transcription.
Indeed, similar to

the deletion

mutant, point

mutation of the

-401 TIE

(GGCTTTGGCGCG to GGCTAATTCGCGC) also eliminated the repressive effect of
TGFβ on the LPA1 promoter activity. However, mutation of the -40 TIE
(GGCTTCGCGCC to GGCAATTCGCC) only slightly reduced the effect of TGFβ,
which was statistically insignificant. Taken together, these experiments indicate that the 401 TIE site is required for TGFβ-Smad mediated repression of the LPA1 gene.
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Figure 3.9. TGFβ represses the transcriptional activity of the LPA1 gene promoter
containing TIEs. A. DNA sequences of two potential TIEs of the human LPA1
promoter were compared with that of the c-myc TIE (A, upper panel). The potential
Smad and E2F4/5 binding sites are underlined. Lower case in the TIE consensus
sequence suggests for preferred nucleotide. The LPA1 promoter (-1156 to +86) was
cloned into pGL2-Basic-Luc to constructed the pGL2-LPA1-Luc luciferase reporter
(WT) (A, lower panel). The deletion (del) and point mutations of each TIE (-401 Mut
and -40 Mut) were made as described in Materials and Methods. B. MDA-MB-231
and SKOV-3 cells were transfected with the indicated plasmids and cultured with or
without TGFβ for 16 hours before luciferase activities were determined. The results
were presented as percentages relative to the values of the cells cultured without TGFβ
(defined as 100%).
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3.3.5 Smad complex binds to the -401 TIE of the LPA1 promoter
To determine whether the Smad complex binds to the LPA1 promoter at the -401
TIE, we performed a DNA pull-down assay using biotinylated double-stranded
oligonucleotides corresponding to the sequences between -413 and -378 that included the
-401 TIE of the LPA1 promoter. MDA-MB-231 and SKOV-3 cells were treated for 1
hour with TGFβ or vehicle. The 36-bp DNA fragment was incubated with cell lysates to
allow binding and precipitating Smad3, Smad4 and E2F4 as detailed in Materials and
Methods. As demonstrated in Fig. 3.10, co-precipitated Smad3, Smad4 and E2F4 were
detected from TGFβ-treated cells but not from vehicle-treated control cells, suggesting
that the 36-bp DNA fragment is capable of binding active Smad3 and E2F4.

Figure 3.10. TGFβ induces occupancy of the Smad complex to the LPA1 gene
promoter. Cell extracts from MDA-MB-231 and SKOV-3 cells untreated or treated
with TGFβ (2.5 ng/ml) for 1 hour were incubated with biotinylated DNA fragment
containing the -401 TIE and strepatavidin beads. The DNA precipitates (DNAP) were
subjected to western blot analysis for Smad3 and E2F4. Whole cell lysates was
included in western blots (WCL) as input.
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To determine if TGFβ induces Smad3, Smad4 and E2F4 binding to the native 401 TIE region of the LPA1 promoter, we performed ChIP assays in MDA-MB-231 and
SKOV-3 cells. The efficiency of anti-Smad3, anti-Smad4 or anti-E2F4 antibody to
precipitate cellular Smad3, Smad4 or E2F4 was illustrated in Fig. 3.11A. qPCR analysis
of Smad3 immunoprecipitates from MDA-MB-231 and SKOV-3 cells showed that TGFβ
induced 3.8- and 3.7-fold increases in Smad3 binding as well as 21.3-fold and 3.9-fold
increase inSmad4 binding to the -401 TIE (Fig. 3.11B). We also observed increases (2.0
and 1.8 fold) in Smad3 binding to the -40 TIE in MDA-MB-231 and SKOV-3,
respectively, however there was no significant increase of Smad4 binding to -40 TIE.
Thus TGFβ induced physical binding of activated Smad3 and Smad4 to the -401 TIE and
to a lesser extent, to the -40 TIE of the LPA1 promoter. The binding of E2F4, another
partner of the Smad complex, to the -401 TIE also increased to 2.5 and 2.7 fold following
TGFβ treatment of MDA-MB-231 and SKOV-3 cells. However, no significant increase
in binding of E2F4 to the -40 TIE in TGFβ-treated MDA-MB-231 cells was observed. In
these ChIP experiments, the binding of Smad3, Smad4 and E2F4 to the c-Myc TIE
sequences in SKOV-3 cells was included as internal positive controls. It has been
reported no TGFβ-mediated repression of c-Myc was found in MDA-MB-231 cells
(Chen et al 2001); therefore, we used binding of Smad3 and Smad4 to PAI-1 SBE as the
positive control. In summary, these experiments provide mechanistic insight into the
TGFβ-mediated repression of LPA1 transcription and LPA1-linked biological activities.
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Figure 3.11. TGFβ induces occupancy of the Smad complex to the LPA1 gene
promoter. ChIP assays were performed to examine the binding of Smad3 and E2F4 to
the -40 and -401 TIEs of the LPA1 promoter and to the c-myc TIE (positive controls).
The immunoprecipitation of Smad3 and E2F4 was verified by western blotting
analysis of immunoprecipitates (IP) and cell lysates (WCL). The binding was
quantitated by qPCR using SYBR Green and the specific primers listed in Table 1.
The results were normalized to the Ct values of inputs and presented as percentages of
inputs. Blank: not detectable.
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3.4 Discussion
In the present study, we showed that the LPA1 gene is a target of TGFβ-mediated
repression. This inhibitory effect of TGFβ on LPA1 expression is detected in both normal
and neoplastic cells with intact TβRs and Smad signaling. Importantly, the inhibition of
LPA1 by TGFβ is sufficient to suppress the LPA1-dependent migratory response to LPA.
The detailed analysis of the underlying mechanism indicates that TGFβ triggers
downregulation of LPA1 through activation of Smad and binding of the Smads-E2F4
complex to the -401 TIE of the LPA1 gene promoter, a process analogous to the welldefined mode of repression of c-Myc by TGFβ (Chen et al 2002).
Among the multiple LPA receptors, LPA1 is the only receptor subtype
transcriptionally repressed by the TGFβ-Smad signaling. In TGFβ-challenged cells,
Smad3 forms a large complex with E2F4/5-p107 and Smad4 in the cytoplasm,
translocates to the nucleus and binds to the TIE motif where the complex recruits HDAC
and silences gene expression (Li et al 1997). Hence both Smad binding site and the
conjugated E2F4/5 element are instrumental to TGFβ repression of target genes (Chen et
al 2002). Extensive analysis of the promoter sequences of other LPA receptors does not
reveal TIE consensus sequence or SBEs in the LPA4 and LPA5 promoters. There are
putative SBEs in the LPA2, LPA3, and LPA6 promoter sequences. However, none of these
SBEs is closely linked to a nearby E2F4/5 binding site or to an ATF3 site. It is intriguing
that the two TIE sites of the LPA1 gene promoter do not function equally. The -401 TIE
was identified to be the major one for Smad-mediated repression of LPA1 while the
contribution of the -40 TIE was negligible. This difference could be attributed to the fact
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that only 4 out of 11 nucleotides match with the consensus E2F4/5 sequence at the -40
TIE while the -401 TIE matches the consensus at 9 out of 11 nucleotides. Alternatively,
the TIE location relative to the transcriptional initiation site or other regulatory sequences
beyond the TIE sites could influence the interaction with the Smad complex and the
transcriptional repression. These possibilities could also explain the irrelevance of the
possible SBE-ATF3 between the two TIEs.
The biological function of LPA1 has been a subject of extensive studies in both in
vitro cell culture and genetic animal models (Santin et al 2009, Shida et al 2003).
Compared to other LPA receptors, LPA1 is most widely expressed (Matas-Rico et al
2008). The nearly ubiquitous distribution of LPA1 has led to the assumption that LPA1 is
constitutively expressed. However, a few recent studies have hinted at the regulation of
LPA1 by intracellular and extracellular cues (Horak et al 2007a, Stadler et al 2006, Xing
et al 2004). The most exciting observation is that LPA1 is one of the target genes
repressed by the metastatic tumor suppressor Nm23 (Marshall et al 2010). Another study
showed that germline polymorphism of fibroblast growth factor receptor 4 (FGFR4) at
residue 388 (G388R) correlates with enhancement of LPA1 expression and more
aggressive migratory and invasive responses to LPA in tumors carrying R388 FGFR4
(Sugiyama et al 2010). Although LPA1 expression may indeed be regulated by Nm23 and
FGFR4, it is not known whether or how these modulators affect transcription, stability or
translation of LPA1. The results from the current study represent the first example that an
endogenous factor transcriptionally restrains expression of LPA1 and LPA1-dependent
cellular effects.
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The roles of LPA and LPA receptors in cancer have drawn considerable attention
in recent years. The LPA2 receptor is overexpressed in ovarian, breast, thyroid and rectal
colon cancers (Hendrix et al 2006, Radvanyi et al 2005, Sanchez-Carbayo et al 2006,
Skrzypczak et al 2010, Su et al 2007). The transgenic and knockout mouse models further
support an oncogenic role of LPA2 (Huang et al 2004, Lin et al 2009). Expression of
LPA1, on the other hand, does not show consensus increases from normal to malignant
phenotypes. Instead, several independent groups have reported a tendency of
downregulation of LPA1 in diverse cancers (Hendrix et al 2006, Murph et al 2008,
Sanchez-Carbayo et al 2006, Shida et al 2004b, Skrzypczak et al 2010, Su et al 2007) in
sharp contrast to the upregulation of LPA2 in malignant diseases. The findings of the
current study offer a plausible explanation to this phenomenon. The enhanced TGFβ
signaling during cancer development and progression may serve as a repressor of
expression of LPA1 but not other LPA receptors.
TGFβ controls a multitude of biological activities in mammalian cells. It inhibits
proliferation of epithelial cells and thus plays a part in early tumor suppression. However,
TGFβ frequently fails to induce growth arrest in transformed epithelial cells. Instead,
TGFβ stimulates migration and invasion of cancer cells, thereby promoting the metastatic
potential in advanced cancer (Bierie and Moses 2006). This presumed effect of TGFβ on
tumor cell invasion and metastasis is largely based on in vitro assays involving only
TGFβ as a motogen (Seton-Rogers et al 2004, Yang et al 2008). The conclusion may not
truly reflect the physiological role of TGFβ in in vivo conditions where tumor cells are
exposed to a complex mix of multiple chemokines, cytokines, nutrients and growth
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factors. We found in the current study that the effects of TGFβ on cell motility could be
opposite under different conditions. In the cancer cell lines we tested, TGFβ itself was a
weak stimulus of tumor cell invasion. In the presence of LPA, however, the role of TGFβ
was reversed, counteracting the strong motogenic activity of LPA. Since both TGFβ and
LPA are present in the circulation and malignant effusions, TGFβ probably acts as a
negative regulator of cell motility in physiological and pathophysiological conditions. By
extension, the findings of the current work underscore the importance of crosstalk
between LPA and other coexisting factors in coordination of the overall cellular
responses.
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CHAPTER 4

GENERAL DISCCUSION

Uncontrolled cell proliferation is a hallmark of cancer. A major drive behind the
uncontrolled proliferation of cancer cells is the activation of growth factor pathways.
Activation of oncogenes and inactivation of tumor suppressors could also sensitize cells
to growth stimuli. A prototype growth factor pathway involved in promotion of
mammalian cell growth is the EGF-EGFR system (Paez et al 2004). Substantial evidence
suggests overexpression or genetic mutations of EGFR in significant percentages of
human malignancies, 69% in nonsmall cell lung cancer NSCLC (da Cunha Santos et al
2011), 50% in breast cancer (Teng et al 2011) and 55%-98% in advanced ovarian
carcinoma (Mustea 2006). In breast and ovarian cancers, HER2, another member of the
EGFR family, is also abnormally overexpressed or activated in up to 30% breast and
ovarian cancers, resulting in more aggressive tumor behaviors and poor prognosis (Tan
and Yu 2007). Recently, the anti-EGFR or HER2 small inhibitors and antibodies have
been used alone or in combination with chemotherapies for treatment of a variety of solid
tumors with significant improvement of patient survivals, confirming the importance of
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the EGFR family in maintaining cancer cell growth and survival (Ciardiello and Tortora
2008).
In contrast to these receptor tyrosine kinases (RTKs), the significance of GPCR,
the largest family of cell surface receptors, in regulation of cancer cells has not been as
well appreciated although significant evidence exists that many GPCR/ligand systems
stimulate proliferation of normal and neoplastic cells. The lysophospholipid mediators
LPA and S1P represent the most characterized and important growth-promoting ligands
acting through GPCRs. Our group was the first to describe overexpression of the LPA2
and LPA3 receptors in ovarian cancer (Fang et al 2004). The overexpression of LPA2 has
since been extended by independent studies to many other types of malignant diseases
including breast cancer, colorectal cancer, gastric cancer, pancreatic cancer, and
differentiated thyroid cancer (Hendrix et al 2006, Radvanyi et al 2005, Sanchez-Carbayo
et al 2006, Skrzypczak et al 2010, Su et al 2007). However, it remains unknown how
LPA mediates oncogenic processes. Substantial studies suggest that crosstalk between
LPA and EGFR or other RTKs plays a role in eliciting the proliferative effect of LPA.
Specifically, LPA transactivates EGFR through production or release of EGFR ligands or
through EGFR ligand-independent interactions between EGFR and GPCR signals. Thus
activation of LPA receptor signal transduction could partially contribute to the
constitutive activity of EGFR to promote proliferation and aggressiveness of cancer cells.
However, this possibility does not exclude EGFR-independent contribution of LPA as
many oncogenic actions of LPA are more robust than those emanating from direct ligand
activation of EGFR as we reported recently (Oyesanya et al 2010, Wu et al 2011).
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In addition to the highly proliferative potential driven by signals from RTKs or
GPCRs, cancer cells may evade growth inhibitory action of TGFβ and the TGFβ family
members (e.g. BMPs, activin). In normal epithelial cells, TGFβ exerts its cytostatic action
through TβR and TβR-activated Smad pathways to induce expression of CDK inhibitors
such as p21, p15 and p27 and to suppress expression of the growth-promoting c-Myc.
However, the cytostatic response to TGFβ is reduced or lost in most malignancies.
Previous studies have identified partial mechanisms for the aberrant TGFβ responses in
cancer, such as genetic mutation or deletion of components of the TGFβ-Smad pathway,
and abnormal expression or functionality of negative regulators of the TGFβ-Smad
pathway and critical transcription factors involved in TGFβ regulation of gene expression.
However, these genetic and epigenetic defects are not common in diverse human tumors
and cannot explain the general compromise of TGFβ growth inhibitory response,
particularly in breast and ovarian cancer cells.
In order to identify the common mechanism underlying the defective TGFβ
responses in breast and ovarian cancer cells, the first part of this dissertation study was
designed to determine whether the cellular response to TGFβ was influenced by other
extracellular factors co-present with TGFβ in tumor microenvironments. LPA is a
ubiquitous growth factor present in serum, could be replenished in serum through serumborne enzyme autotaxin or produced by tumor cells in culture. Our original hypothesis
was that the abnormally active LPA signaling might confer overwhelmingly strong
proliferative cues beyond the capacity of the TGFβ to overcome. However, our data
demonstrates that the mitogenic activity of LPA does not contribute to the resistance of
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breast and ovarian cancer cells to TGFβ. LPA shows a general mitogenic activity towards
both TGFβ-sensitive and resistant breast and ovarian cancer cells. Instead, we observed a
correlation of TGFβ responsiveness with LPA induction of p21 in breast and ovarian
cancer cell lines. The CDK inhibitor p21 is a well-known TGFβ cytostatic response gene.
Surprisingly, TGFβ alone only weakly induces p21 expression even in the TGFβresponsive breast and ovarian cancer cell lines. Only in the presence of serum or serumborne LPA, a full-magnitude elevation of p21 expression is observed. We further
confirmed that LPA acts in concert with TGFβ in inducing p21 expression.
Downregulation of p21 induction by p21 siRNA in TGFβ-responsive cells or induction of
p21 with other known stimuli such as TPA in TGFβ-resistant cells leads to reversal of
responsiveness to TGFβ. Hence, the combined effect of LPA and TGFβ on p21 induction
is critical to TGFβ-mediated growth inhibition in TGFβ-sensitive breast and ovarian
cancer cells. On the contrary, in the TGFβ-resistant cells, LPA does not stimulate p21
expression or cooperates with TGFβ to induce p21. Therefore, lack of p21 inducibility by
LPA is potentially linked to the loss or impairment of the cytostatic response to TGFβ
seen in many breast and ovarian cancers.
It remains to be determined how LPA induction of p21 is differentially regulated
between TGFβ-sensitive and resistant cells. In our experiments, LPA induces p21
expression through LPA1 and LPA2 receptors. Knockdown of LPA1 or LPA2 partially
compromises p21 expression induced by LPA. Since both of these receptors are present
in most breast and ovarian cancer cell lines irrespective of their TGFβ response statuses,
it is unlikely LPA1 and LPA2 levels are primary determinants of the differential p21
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induction in these cells. The Erk activation is also a generic response to LPA among
breast and ovarian cancer cell lines. In our study, we further demonstrate that the C/EBPβ
transcription factor downstream of Erk mediates p21 induction by LPA. Coincidently,
C/EBPβ is a transcription factor crucial to induction of another TGFβ cytostatic gene p15
(Gartel and Tyner 1999). In metastatic breast cancer cells, the transcriptional activity of
C/EBPβ is inhibited by an excess of LIP (liver inhibitory protein), an inhibitory,
truncated form of C/EBPβ. It is possible that the presence of high levels of endogenous
LIP could prevent LPA-induced p21 expression and TGFβ cytostatic response. It will be
of interest to examine expression of LIP in TGFβ-resistant versus sensitive breast and
ovarian cancer cells.
Another important observation made from the first part of my study is that p21 is
essential but not sufficient to render breast and ovarian cancer cells sensitive to TGFβ.
LPA alone induces significant expression of p21 in TGFβ-sensitive MBA-MB-231 and
Caov-3 cells, which is associated with growth promotion rather than inhibition. In TGFβresistant breast and ovarian cancer cell lines, TPA by itself induces p21 expression but
does not affect proliferation of these cells. These results suggest that another TGFβmediated effector cooperates with increased p21 to halt cell cycle progression. This is
consistent with the fact that the TGFβ-resistant breast and ovarian cancer cell lines we
examined also possess functional TβRs and Smad3 signaling. In these otherwise TGFβresistant cells, the cytostatic sensitivity to TGFβ could be reconstituted through TGFβindependent induction or activation of p21. Therefore, in the future, p21 activating or
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inducing agents could be pursued in conjunction with TGFβ to develop new therapies
against breast and ovarian cancer.
In the second part of this study, we extended to examine the crosstalk between
LPA and TGFβ in modulation of cell migration and invasion. Activation of tumor cell
motility is one of the critical steps leading to tumor invasion and distant metastasis.
Different from the cooperative effects of LPA and TGFβ on p21 induction to control cell
proliferation, TGFβ dramatically antagonizes LPA-induced migration and invasion of
breast and ovarian cancer cells. A 30-50% decrease in migration and 60-80% reduction in
invasion are observed in the presence of TGFβ although TGFβ alone weakly promotes
cell migration and invasion of breast and ovarian cancer cell lines. The inhibitory effect
of TGFβ on LPA-dependent cell migration and invasion is manifest in all cancer cell
lines with functional TβRs and Smad3 including those resistant to cytostatic effect of
TGFβ, suggesting that TGFβ down-regulates the motogenic activity of LPA via a
mechanism independent of the cytostatic effectors of TGFβ.
LPA stimulates cell motility through activation of Rac and Rho in a coordinate
manner. Rac promotes lamellipodia protrusion and forward movement, whereas RhoA
regulates actomyosin-driven cytoskeleton contraction and detachment of the rear of
migrating cells. Since LPA1 plays a primary role in LPA stimulation of Rac and Rho and
the subsequent migration and invasion (Van Leeuwen et al 2003), we tested the
possibility that TGFβ may repress expression of LPA1 to inhibit LPA-induced cell
motility. The qPCR analysis of multiple breast and ovarian cancer cell lines as well as
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their normal and immortalized epithelial counterparts show that TGFβ treatment induces
30-70% decreases in LPA1 mRNA. The TGFβ-induced downregulation of LPA1 is
further supported by a coincident finding of microarray analysis from our collaborator Dr.
Deborah Lebman that LPA1 mRNA is inhibited by TGFβ treatment of the OE33
esophageal cancer cell line. In the literature, a microarray study of TGFβ transcriptome in
human pituitary cells also revealed that LPA1 is one of 109 genes repressed by TGFβ
although the finding was not validated or pursued by individual gene expression and
function analyses (Ruebel et al 2008).
We next explored how TGFβ represses LPA1 expression. In contrast to wellstudied SBE-dependent gene activation by TGFβ, the molecular mechanism for TGFβmediated gene repression is only partially understood through studies of two prototype
genes repressed by TGFβ, namely c-Myc and Id1. The c-Myc gene p1 promoter contains
TIE element made of an SBE and a closely linked E2F4/5 cis element that allows binding
of the Smad3/4-E2F4/5-p107 complex to limit transcription of c-Myc. TGFβ inhibition of
Id1 is executed through binding of the Smad-ATF3 complex to an SBE site and a nearby
CREB element on the Id1 promoter. Interestingly, the LPA1 gene promoter contains two
putative TIE sites (-401 TIE and -40 TIE), each consisting of an SBE site and a flanking
E2F4/5 element, analogous to TIE present on the c-Myc gene promoter. As described in
detail in Chapter 3, we demonstrated that TGFβ represses LPA1 transcription through
binding of the Smad3/4-E2F4/5-p107 complex to the -401 TIE of the LPA1 gene
promoter. The proximal -40 TIE does not seem to be involved in TGFβ repression of
LPA1 transcription. The conclusion is drawn from substantial evidence from multiple
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molecular approaches including luciferase reporter assay, site-directed mutagenesis of the
TIEs, TIE DNA precipitation of cellular Smads and E2F4 protein, ChIP assays of TGFβinduced recruitment of the Smad3/4-E2F4 complex to the native -401 TIE sequence of
the LPA1 promoter, and shRNA knockdown of Smads.
The identification of LPA1 as a novel physiological target of TGFβ-mediated
repression is a significant advance in LPA biology. Little is known about how LPA1 is
transcriptionally regulated. Our results provide the first mechanistic insight into
transcriptional control of LPA1. Different from LPA2 that is generally overexpressed in
cancer, LPA1 is down-regulated in a variety of cancer lineages including ovarian, bladder,
colorectal and breast cancers (Hendrix et al 2006, Murph et al 2008, Sanchez-Carbayo et
al 2006, Shida et al 2004b, Skrzypczak et al 2010, Su et al 2007). The TGFβ repression
of LPA1 may offer a plausible explanation of the cancer-associated downregulation of
LPA1. Despite the common loss of the cytostatic response to TGFβ, most cancer cells
exhibit intact TβRs and Smad signaling, which could lead to transcriptional repression of
LPA1, in particular when TGFβ levels are elevated in advanced cancers.
Furthermore, TGFβ repression of LPA1 is functionally sufficient to inhibit LPA1dependent cell migration and invasion. This observation sheds new light on the
physiological role of TGFβ in regulation of tumor cell invasion and metastasis. TGFβ has
been shown to positively regulate tumor cell motility. In our hands, we detected a weak
and sometimes statistically insignificant migratory activity of TGFβ in breast and ovarian
cancer cell lines. However, the activity of TGFβ is minimal compared to that of LPA.
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Given the fact that these two factors are elevated and co-present in tumor
microenvironments, TGFβ most likely neutralizes the robust migratory activity of LPA
and therefore may function to prevent tumor cell invasion and metastasis in vivo. This
argument, however, is contrary to the current dogma in the field of TGFβ biology. The
evidence for the pro-metastatic role of TGFβ has been largely derived from analysis of
TGFβ alone in in vitro migration and invasion assays. The results of the present study
underscore the need to revisit these effects of TGFβ in more physiologically relevant
conditions or using in vivo models. As a general rule, the interactions among coexisting
chemokines, cytokines, growth factors and nutrients should be taken into consideration
during functional analysis of biological factors.
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